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Abstract
Individuals born with primary immune deficiency diseases (PIDD) have a dysfunctional
immune system, and many are treated by lifelong injections of immunoglobulin therapy.
Studies have shown that these patients have low health-related quality of life (HRQOL)
and well-being (WB) and that these outcomes might be improved by the availability of
therapy innovated according to preferences for fewer needle sticks or a shorter infusion
time. Regulators at the U.S. Food and Drug Administration (FDA) have approved
therapies innovated per these preferences. However, there is limited data demonstrating
how these innovations impact HRQOL and WB. Using the biopsychosocial model, the
purpose of this cross sectional quantitative study was to evaluate whether patients with
PIDD using therapies innovated for fewer needle sticks or a shorter infusion time had a
higher mean HRQOL and WB compared to those who were not. The study included 153
patients who completed the Patient Reported Outcomes Measurement Information
System (PROMIS)-29 survey. The dependent variables were HRQOL and WB measured
by PROMIS-29, and the independent variables were the medical product innovations.
Independent samples t tests results showed mean PROMIS-29 scores were not
statistically different (p > .05). This suggests patients were optimized according to their
treatment preference. A subgroup of patients who had taken the PROMIS-29 survey
more than once concurrent with switching to a therapy aligned with patient preferences
showed improved HRQOL and WB. These findings have implications for positive social
change in that seeking the patient’s voice to inform medical product innovation and FDA
regulatory decision-making has potential to improve biopsychosocial outcomes.
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Chapter 1: Introduction to the Study
Introduction
Primary immune deficiency disease (PIDD) comprises a group of more than 230
different rare genetic disorders where immune system cells, antibodies, and complement
proteins are missing, defective, or present in insufficient amounts (Chapel et al., 2014).
Persons with an immune system deficiency have greater susceptibility to common and
unusual infections which are chronic, more severe, of longer duration, and are more
difficult to treat with standard medical care, compared to individuals with an intact
immune system (Chapel et al., 2014; Costa-Carvalho et al., 2014; Heath, Lehman,
Saunders, & Craig, 2016). Examples of the effects of immune system deficiency include
bone, gastrointestinal, mucous membrane, and respiratory infections; abscesses of the
brain, liver, or lungs; autoimmune diseases (due to an improperly functioning immune
system) leading to anemia, arthritis, or asthma; abnormal gland development; heart
defects; and increased cancer risk (American Academy of Asthma, Allergy, and
Immunology, 2016; Costa-Carvalho et al., 2014).
In the United States, researchers estimate prevalence of PIDD to be 1 in 2000
children, 1 in 1200 individuals, and 1 in 600 households (Jiang, Torgerson, & Ayars,
2015; Melamed, Testori, & Spirer, 2012). The rarity of PIDD raises public health
concerns and merits study because delayed diagnosis often results in life-threatening
illnesses and in high costs from greater use of health care services, such as emergency
room visits and hospital admittance prior to the individual receiving effective treatment
(Chapel et al., 2014; Resnick, Bhatt, Sidi, & Cunningham-Rundles, 2013). Haddad,
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Barnes, and Kafal (2012) cited survey results that revealed an average 9-year delay from
presentation of symptoms to diagnosis. Haddad et al. also commented on low PIDD
awareness in the medical community as a possible cause for the delay in diagnosis.
Menzin, Sussman, Munsell, and Zbrozek (2014) determined the mean PIDD infectionrelated medical costs, over a seven month period in 2010, to be U.S. $11,925 per patient.
The overall mean cost per patient included the following individual patient costs: an
emergency visit ($899), an outpatient visit ($1,460), and an inpatient hospital visit
($38,574; Menzin et al., 2014). Jiang, Torgerson, and Ayars (2015) found a 1.7%
increased risk of death with each year of delayed diagnosis, and a 4.5% increased risk of
death with each increase in chronological age at diagnosis.
Although there is no treatment for PIDD that can repair the immune system to
normal function, lifelong (after diagnosis) immunoglobulin antibody replacement therapy
is an option for many patients. Medical product manufacturers have developed
immunoglobulin replacement therapies for PIDD treatment and have made these
therapies available to patients through their medical practitioners, subsequent to approval
by the Food and Drug Administration (FDA; FDA, 2015b). Thus, medical practitioners
are prescribing lifelong regular infusions of immunoglobulins (also referred to as immune
globulins or antibodies) for PIDD treatment (Menzin, Sussman, Munsell, & Zbrozek,
2014). Moreover, medical product manufacturers have conducted clinical trials
demonstrating the safety and efficacy of immunoglobulin replacement therapy based on
biomedical endpoints such as blood levels of immunoglobulin (Melamed et al., 2012).
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The FDA has subsequently approved a number of these medical products for
immunoglobulin replacement therapy (Schroeder & Dougherty, 2012).
Though immunoglobulin replacement therapies are available, the biomedical and
the psychosocial burdens that patients face daily, and for an extended duration of time
with chronic diseases such as PIDD, are a serious global public health concern (Heath et
al., 2016; Hirsch, Walker, Chang, & Lyness, 2012). Examples of some of the burdens
that patients with PIDD face include decreased health-related quality of life (HRQOL)
due to anxiety and depression around fear of infection, missed days of school or work,
inability to work; and feelings of isolation due to the inability to function socially with
friends and family and as a member of society (Bienvenu et al., 2016). Menzin et al.
(2014) cited a Jeffrey Modell Centers Network survey which showed that the average
patient with PIDD has 70 emergency room visits, 19 hospitalizations, and 34 missed days
of school or work in the year preceding diagnosis. These numbers underscore the public
health issue for patients with PIDD.
Although immunoglobulin replacement therapy (IGRT) mitigates some of the
biomedical and psychosocial burdens of PIDD caused by recurrent infections (Melamed
et al., 2012), the life-long therapy regimen creates other biomedical and psychosocial
burdens. Examples of life-long therapy burdens include systemic and localized reactions
to therapy; travel to an infusion clinic and wait time at the clinic; and frequency, duration,
and route of therapy administration (Dashti-Khavidaki et al., 2009; Haddad, Barnes, &
Kafal, 2012). Because immunoglobulin replacement therapy is administered
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intravascularly, needles are involved; thus, needle sticks are also a burden (Espanol,
Prevot, Drabwell, Sondhi, & Olding, 2014).
To address these issues, researchers, medical products manufacturers, and the
FDA are currently seeking more patient input regarding treatment preferences and
treatment psychosocial outcomes, such as HRQOL and well-being. Patient treatment
preferences have informed innovations in therapies developed by medical product
manufacturers, which are now FDA-approved and commercially available. Examples of
innovative therapies include treatments which enable patients to self-administer
medication in their home instead of intravenous infusions administered in a clinical
setting by a medical practitioner (Jiang et al., 2015). Additionally, in 2014 the FDA
approved a therapy that patients can self-administer with fewer needle sticks and in a
shorter time per infusion (Espanol et al., 2014; Garduff & Nicoloay, 2006; Ponsford et
al., 2015; Wasserman, 2014).
Individuals researching treatment regimens indicated for patients with PIDD
might also elect to use validated survey instruments as a tool for assessing patient
psychosocial outcomes (such as HRQOL and well-being). Researchers have studied
HRQOL and well-being in patients with PIDD focusing on location of therapy
administration, route of administration, and patient preferences related to therapy
frequency, duration, and number of needle sticks, using standard validated survey
instruments such as the EuroQOL five-dimension questionnaire (EQ-5D) and the Short
Form Health Survey (SF-36; Espanol et al., 2014; Jiang et al., 2015; Tabolli et al., 2014;
Vultaggio et al., 2015). Researchers with the National Institutes of Health (NIH)
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developed the Patient-Reported Outcomes Measurement Information System (PROMIS)
survey instruments to gather HRQOL and well-being information and to measure health
outcomes from the patient’s perspective about chronic diseases globally (NIH, 2017). In
addition, the Immune Deficiency Foundation (IDF), an advocacy organization for
patients with PIDD, is partnering with the NIH to administer the abbreviated PROMIS
(called PROMIS-29) survey instrument to individuals from IDF’s patient registry (C.
Scalchunes, personal communication, October 20, 2016). In this study I present the first
findings of HRQOL and well-being of patients with PIDD as measured by the PROMIS29 survey instrument.
The goal of this study was to evaluate whether medical product innovations based
on patient treatment preferences for number of needle sticks and infusion time improve
HRQOL and well-being, as measured by the PROMIS-29 instrument. The implications
of this study for positive social change include providing additional evidence supporting
the gathering and use of patient preferences in medical product development and
regulatory decision-making. Findings may encourage researchers, manufacturers, and
regulators to shift from a purely biomedical (or clinical) focus to a psychosocial (or
public health) one whereby they consider the psychosocial impact of therapy innovation.
Incorporating this type of focus and considering patient preferences for treatment may
result in improved HRQOL and well-being for patients with PIDD.
Background
Patients have access to medical products because there exists a supply chain from
medical product manufacturers, though regulatory authority (i.e. FDA) review and
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approval, to recognition of the medical product by insurance companies and distribution
to pharmacies, and culminating with a physician’s prescription (FDA, 2015b).
Researchers, manufacturers, regulatory authorities, and medical practitioners seek patient
feedback (or patient-reported outcomes) according to their role within the medical
products supply chain. For instance, medical product manufacturers might want to
understand treatment satisfaction and patient preferences for treatment as they innovate
medical products designed to reduce the burden chronic disease poses to the patient on a
daily basis; regulatory authorities might be interested in HRQOL reports to establish a
risk to benefit profile as they review a medical product application; and medical
practitioners might seek to evaluate patient reports of health status and adherence to
regimen as they talk with the patient regarding an optimal treatment plan (Willke, Burke,
& Erickson, 2004). Willke, Burke, and Erickson (2004) reviewed drug medical product
labeling between the years 1997-2002 to determine the extent to which patient-reported
outcomes were used for medical product manufacturers’ drug innovation and for
regulatory review and approval by FDA. Willke et al. (2004) found patient-reported
outcomes were reported in 30% (64 of 215) of the labels reviewed, behind clinical
endpoints (62%) and laboratory endpoints (50%). According to their review, the medical
products innovated and approved using patient-reported outcomes were used to treat
inflammation, conjunctivitis; and disorders of the central nervous, gastrointestinal,
respiratory, eye, and urologic systems (Willke et al., 2004).
The theoretical framework for this dissertation stems from the concept that
medical products are innovated not only to alleviate the clinical presentation of disease,
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but also to help patients manage their lives while also managing a disease state which
cannot be cured. In this study, I focused on two aspects of PIDD management which the
literature suggested patients expressed a desire to improve: (a) reduction in the number of
needle sticks and (b) shorter infusion time, but where there is currently limited data
showing whether these medical product innovations result in better outcomes in terms of
HRQOL and well-being; hence there is a gap in knowledge.
Biomedical evidence that a medical product works and has benefits to the patient
which outweigh the risks is demonstrated through clinical trials. The literature is replete
with studies showing that immunoglobulin replacement therapy boosts the immune
system of patients with PIDD. The goal of this study, and the reason why the study was
needed, was to bring medical product innovation into the public health discipline by
seeking to generate evidence that a medical product works and also has benefits of
improved patient HRQOL and well-being because psychosocial parameters of patient
preference for treatment were considered by medical product manufacturers in their
development of the medical product.
To make this dissertation more relatable to the reader who is less familiar with
rare diseases such as PIDD, I used this section to make an analogy of PIDD (a rare
disease) to Type 2 diabetes (a common disease). Like PIDD, individuals with Type 2
diabetes have a condition where the primary defect (in the case of diabetes, cells cannot
uptake insulin) impacts other body systems and leads to comorbidities. Additionally, the
disease states are comparable in that neither can be cured, but with management, medical
treatment enables the patient to live for decades. Thus, management of routine life
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activities while always in a chronic disease state comes to the forefront in terms of impact
to HRQOL and well-being. Presented below is a direct-to-consumer advertisement for a
new drug treatment for Type 2 diabetes. The biomedical statement in the promotion
reads: “Trulicity, along with diet and exercise, may help lower your blood sugar and
A1C.” (How Trulicity can help, 2017, para 1).
The promotion goes on in the biomedical framework to comment on a clinical
trial to demonstrate lower blood sugar and A1C levels: “In a study, the higher dose
helped 78% of people and the lower dose helped 66% of people get to the A1C goal of
below 7%.” (How Trulicity can help 2017, para 1). Next, the patient is informed about
the innovation of Trulicity, and how the innovation might cater to patient preferences for
treatment with this statement:
Trulicity is designed to be taken once a week, which may help you fit it into your
busy life. You can take Trulicity any time of day, with or without meals. Just
pick which day of the week will be your Trulicity Day and remember to keep
taking it that day, every week. (How Trulicity can help, 2017, para 4)
The promotion is silent regarding impact on HRQOL and well-being. However,
Fisher, Tang, and Polonsky (2017) introduced their paper by commenting on the advent
of medical products innovated for achieving glycemic control and the associated interest
among, for example, researchers, FDA, and patients regarding measures of quality of life
and well-being. The authors pointed out that glycemic control is generally a primary
measure but that patients and other stakeholders consider equally important the secondary
or tertiary measures of quality of life (Fisher, Tang, & Polonsky, 2017).
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Likewise, the literature and direct-to-consumer advertising demonstrate that
medical product innovations in the treatment of PIDD still meet clinical criteria of
boosting the immune system, while also offering patients flexibility to live their life; for
example, to self-administer therapy wherever they might be physically located and at a
time of their choosing.
The gap in knowledge this study aimed to fill is whether there were any
differences in HRQOL and well-being between patients with PIDD who use medical
products innovated for fewer needles sticks or for shorter infusion times versus those who
do not. Since patient preferences contributed to medical products manufacturers’
innovation of new medical products, this study was needed to understand whether the
resultant innovated medical products improved HRQOL and well-being, as measured by
PROMIS-29, for patients with PIDD.
Problem Statement
The problem I addressed is the gap in the literature concerning whether medical
products innovated per patient preferences for fewer needles sticks and shorter infusion
times resulted in improved HRQOL and well-being, as measured by PROMIS-29, for
patients with PIDD. Factors associated with poorer HRQOL include comorbidities,
unemployment, stress, multiple infections, and PIDD diagnosis delay (Jiang et al., 2015).
Factors associated with improved HRQOL include home-based therapy; treatment
comfort, flexibility, convenience, and independence; shorter treatment duration and less
impact/disruption to daily activities (e.g., school/work and social); and satisfactory
immunoglobulin trough levels (Jiang et al., 2015; Vultaggio et al., 2015).
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Additional to evaluating patients’ treatment preferences, researchers also
evaluated patients’ satisfaction with treatment. Espanol, Prevot, Drabwell, Sondhi, and
Olding (2014) found that the majority of patients with PIDD (76%, n = 300) were pleased
with their current treatment; however, those receiving SCIG (83%) were more pleased
compared to those receiving IVIG (69%). Additionally, Espanol et al. (2014) compared
SCIG with IVIG in terms of impact on HRQOL measures of anxiety, depression,
mobility, routine activity performance, pain, and self-care. The researchers’ analysis
revealed there was no difference in HRQOL (71.8% and 71.9%, respectively) as
measured by the EQ-5D (Espanol et al., 2014). Deshpande, Rajan, Sudeepthi, and Nazir
(2011) noted that assessing patient-reported outcomes is an important component to
understanding patient compliance with treatment, improvements to medical products, and
better patient outcomes such as quality of life related to medical treatment. Based on my
review, the literature has not yet been expanded to present the changes in HRQOL and
well-being as dependent variables to recent medical product innovations allowing for
fewer needle sticks and offering shorter infusion duration using the PROMIS-29
instrument in a population of patients with PIDD.
Purpose of the Study
The purpose of this quantitative study was to compare the mean differences in
HRQOL and well-being as measured by PROMIS-29 for patients with PIDD who used
medical product manufacturers’ innovative medical products designed to require (a)
fewer needle sticks or (b) shorter infusion time to patients who did not use such products.
The dependent variables were PROMIS-29 instrument measures of anxiety and
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depression as proxies of HRQOL and participation in social roles/activities as a proxy of
well-being (HealthyPeople.gov, 2017). My overarching purpose is to help patients who
have a chronic disease state which cannot be cured and can only be managed via a regular
treatment routine to have optimal HRQOL and well-being. The results of this research
have the potential to add to the body of scientific knowledge and provide support for
patient-reported outcomes of HRQOL and well-being as valid inputs in medical product
development and FDA regulatory decision-making.
Research Questions and Hypotheses
Research Question 1: Is there a difference in the well-being proxy PROMIS score
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who
report using medical products innovated to offer therapeutic dosing with one needle stick
every 3 or 4 weeks compared to those who report using medical products innovated to
offer therapeutic dosing with more than one needle stick every 3 or 4 weeks?
H01: The mean differences are not statistically significant.
Ha1: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 2: Is there a difference in the HRQOL proxy PROMIS score
for “Anxiety” between patients with PIDD who report using medical products innovated
to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared to those
who report using medical products innovated to offer therapeutic dosing with more than
one needle stick every 3 or 4 weeks?
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H02: The mean differences are not statistically significant.
Ha2: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 3: Is there a difference in the HRQOL proxy PROMIS score
for “Depression” between patients with PIDD who report using medical products
innovated to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared
to those who report using medical products innovated to offer therapeutic dosing with
more than one needle stick every 3 or 4 weeks?
H03: The mean differences are not statistically significant.
Ha3: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 4: Is there a difference in the well-being proxy PROMIS score
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who
report using medical products innovated for shorter infusion time compared to those who
report using medical products not innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford et al.,
2015).
H04: The mean differences are not statistically significant.
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Ha4: The mean differences are statistically significant.
The independent variable was infusion time duration, and the dependent variable was
PROMIS score (Likert scale mean).
Research Question 5: Is there a difference in the HRQOL proxy PROMIS score
for “Anxiety” between patients with PIDD who report using medical products innovated
for shorter infusion time compared to those who report using medical products not
innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al.,
2015).
H05: The mean differences are not statistically significant.
Ha5: The mean differences are statistically significant.
The independent variable was infusion time duration, and the dependent variable was
PROMIS score (Likert scale mean).
Research Question 6: Is there a difference in the HRQOL proxy PROMIS score
for “Depression” between patients with PIDD who report using medical products
innovated for shorter infusion time compared to those who report using medical products
not innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
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to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al.,
2015).
H06: The mean differences are not statistically significant.
Ha6: The mean differences are statistically significant.
The independent variable was infusion time duration, and dependent variable was
PROMIS score (Likert scale mean).
Theoretical Framework
The theoretical framework used for this dissertation was George Engel’s (1977)
biopsychosocial model, which is found within medical sociology and derived from the
understanding among sociologists and physicians, that there is an interplay between
biology, culture, social determinants of health, and the environment which influence
whether, and how, people become ill (also the duration, intensity, and type of illness
manifestation) from a given cause. George Engel (1977) introduced the biopsychosocial
model as a counter to the biomedical approach toward the practice of medicine. Engel
posited that the biomedical model was inadequate as it reduced the patient to his or her
body parts and biochemical elements. However, Engel argued, the patient is a whole
being with senses and experiences. Thus, the patient is a composite of biological,
psychological, and social systems and sub-systems, none of which exists in isolation from
the others.
Physicians use the biopsychosocial model as a model for patient interaction, and
as a framework for how the physician can view the patient and provide care (Engel, 1977;
Engel, 1980; Haveilka, Lcuanin, & Lcuanin, 2009). Medical product manufacturers and
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regulatory authorities can use this framework in a way that they can observe the patient
who will use the medical products once approved. In medical sociology, illness is
described in the broader term encompassing sickness caused by microorganisms or
physiologic malfunction (e. g. flu, diabetes, or HIV/AIDS) and illness related to daily
living (e. g. depression, stress, or fatigue) (Cockerham, 1981). Albrecht and Devlieger
(1999) postulated via the disability paradox framework that people with debilitating
illness can experience an excellent quality of life. I used the disability paradox
framework as a basis for including a well-being measure in this study (Albrecht &
Devlieger, 1999; Fellinghauer, Reinhardt, Stucki & Bickenbach, 2012). My use of the
biopsychosocial model can help determine if consideration of patients’ perspectives,
incorporated into drug development, results in better outcomes in terms of HRQOL and
well-being.
Nature of the Study
I used quantitative methodology to analyze patient registry data from the United
States Immunodeficiency Network (USIDNET) to understand mean changes in HRQOL
and well-being as measured by the NIH sponsored PROMIS-29 instrument. The
objective for this study was to measure differences in HRQOL scores and well-being of
patients with PIDD based on patient preferences for treatment; namely, number of needle
sticks and infusion time using the biopsychosocial model framework to explain the
relationship between the independent and dependent variables.
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Definitions
Ability to participate in social roles/ activities: The ability to participate in social
roles/activities bank of PROMIS questions focuses on feelings of well-being or thriving
as individuals participate in their typical societal roles and social relationships (Bode,
Hahn, DeVellis, & Cella, 2013).
Anxiety: The anxiety bank of PROMIS questions focuses on feelings of fear,
dread, and nervousness which might be accompanied by cardiovascular system response
and dizziness (Schalet et al., 2016)
Depression: The depression bank of PROMIS questions focuses on feelings of
sadness, guilt, low self-worth, loneliness, and disinterest in life (“Depression: A Brief
Guide,” 2017).
Food and Drug Administration: As related to this dissertation, FDA is a
governmental agency under the Department of Health and Human Services charged with
protecting public health by ensuring the availability of safe, effective, and innovative
medical products and advancing public health through provision of science-based,
publicly available information (FDA, 2015c).
Health-related quality of life (HRQOL/ HRQL): The subjective measure of patient
perceptions of their physical, social, and emotional functioning with one or more chronic
diseases (Elliott & Richardson, 2014).
Patient-centered: An approach which encompasses the biopsychosocial
theoretical framework in that it is inclusive of patients or their proxies (e.g., a caregiver,
parent, or advocate; Kalra, 2014). This approach involves considering patients’ and/or
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proxy members’ opinions and contributions to decision-making in all aspects of care,
from medical product development through regulatory approval to type of treatment
prescribed by a medical practitioner and pharmacy provider (Kalra, 2014).
Patient-reported outcomes (PRO): A self-assessed measure of health status which
is independent of a clinical analysis or medical professional evaluation (Nicassio et al.,
2011).
Perceived health: An individual’s subjective assessment of his or her biological,
cultural, social, and psychological functioning which can be used as an indicator of
patient satisfaction with his or her health and with medical treatments (Seeborg et al.,
2015)
Primary immune deficiency disease (primary immune deficiency disorder): A
group of rare genetic diseases in which components of the immune system are missing or
defective, resulting in a tendency to have unusual infections which are more severe and
last longer than in individuals with an intact immune system (IDF, 2016).
Route of administration: The pathway by which medication is introduced to the
body. Injection routes of administrations discussed here include intramuscular (IM),
intravenous (IV), and subcutaneous (SC). Injection routes of administration of immune
globulin (IG) for PIDD are described using the terms IMIG, IVIG, and SCIG (Kobrynski,
2012).
Well-being: A measure of how people are coping in a positive way and also
thriving with chronic disease (Barile et al., 2013).
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Assumptions
I made two assumptions for this study. The first assumption was that the
USIDNET patient registry from which I obtained study data is representative of the
general PIDD population in the United States and of the PIDD patient population whose
treatment preferences informed drug innovation. The second assumption was that the
PROMIS-29 measures are relevant for the PIDD population.
Scope and Delimitations
Firstly, not all medical products are specified for pediatric patients. Therefore,
the study plan was to include patients who were 16 years old and older at the time they
took the survey. I used a liberal definition of adulthood to select the age 16 years and
older. The rationale stemmed from concerns regarding sample size due to the rareness of
PIDD, and that each state defines its criterion of adulthood for various purposes. For this
study, age 16 represented the two states (New York and North Carolina) where criminal
offenders would be tried in an adult court (National Conference of State Legislatures,
2017). Secondly, there are several categories of PIDD. This study captured all the
categories under the general heading PIDD and I did not segment according to PIDD
subtype.
Limitations
Blome and Augustin (2015) presented views of the types of biases which exist
when measuring changes in HRQOL prospectively and retrospectively. The research
proposed here is a retrospective study where researchers collect data only after an
intervention. Respondents can take the survey semiannually. Retrospective studies are
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subject to recall bias, where the respondent either recalls their past situation as being
either better or worse than their current situation, based on how they feel when taking the
assessment or a respondent reconstructs their response based on current feelings and
assumptions about their past status (Blome & Augustine, 2015). A second category of
bias relates to how subjects respond to survey questions. The tendency to answer in
agreement, answer in disagreement, disregard questions deemed as not applicable to the
subject’s situation, answer randomly, answer at the extremes, or answer in a manner the
subject deems is more socially acceptable creates bias (Blome & Augustine, 2015).
Blome and Augustine (2015) suggested a retrospective study even with the listed biases
could be beneficial when one wants to understand patient views on treatment benefits.
Fayers, Langston, and Robertson (2007) described response error in
measurements of quality of life (QOL). The authors posited that QOL bias is introduced
regarding the frame of reference the subject uses when responding to the survey
instrument (Fayers, Langston, & Robertson, 2007). The frame of reference could be a
comparison to: self, prior to illness; self, the previous time point in a longitudinal study;
other patients with the same disease; patients with a different disease; and healthy
subjects. At each interval of measurement, the frame of reference can shift. Upon testing
for mean differences in subjects’ expressed frame of reference against QOL scores, there
were statistically significant differences according to frame of reference (Fayers et al.,
2007).
Lastly, the sample size was expected to be small due to the rareness of PIDD, and
randomization was not possible. Limitations were addressed via statistical analytical
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methods additional to t-tests as warranted by the data. Additionally, limitations are
acknowledged in the methodology and conclusion chapters.
Significance of the Study
Information gained from this study could help the primary immunodeficiency
community understand changes (hopefully improvements) in HRQOL and well-being
parameters resulting from using different medical product innovations enabling
flexibility. For example, patient perspectives can inform drug development and even the
regulatory process for drug approval. Once the drug is developed and on the market,
which of the patient perspectives (specifically related to social parameters measured with
instruments measuring HRQOL and well-being parameters) changed because of using a
given drug? Such knowledge could be useful for refining drug development protocol and
regulatory policy in the future.
Summary
In this chapter, I presented information about PIDD, the role of medical product
manufactures as it relates to HRQOL and well-being, the relevance of PIDD to public
health, and a theoretical lens through which PIDD can be viewed. In the next chapter, I
establish the basis for the study by reviewing existing literature and identifying gaps in
the literature. Some of the areas reviewed include the biopsychosocial model theoretical
framework, and key variables I used in my study.
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Chapter 2: Literature Review
Introduction
Medical products manufacturers have innovated therapies for patients with PIDD
based on patient preferences for fewer needle sticks and a shorter infusion time with the
goal of improving these patients’ HRQOL and well-being (Espanol et al., 2014;
Kobrynski, 2012; Ponsford et al., 2015). Since 2015, the IDF through USIDNET has
been collecting HRQOL and well-being data on patients with PIDD through the
PROMIS-29 survey instrument. There is limited data showing whether therapies
innovated for fewer needle sticks and shorter infusion time have an impact on HRQOL
and well-being as measured by PROMIS-29. The purpose of this quantitative study was
to determine the mean differences in HRQOL and well-being using PROMIS-29 scores
of patients with PIDD who are using medical product manufacturers’ innovative medical
products allowing for (a) fewer needle sticks and (b) shorter infusion time compared to
those who were not.
This literature review begins with the search strategy I used for locating literature.
I then present the biopsychosocial model theoretical framework and supporting studies.
Next, I present an extensive literature review of key variables and concepts. Lastly, I
conclude with the gap found in the literature which my study aimed to fill, and with a
summary of the chapter.
Literature Search Strategy
Although the tone of the literature review is neutral and is based on the positivist
tradition of biomedical research (see Wilson, 2000), it suggests the need to expand
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beyond physiological parameters of biomedical research to include psychosocial
parameters, along with patient experience (Mead & Bower, 2000). The literature review
was conceptual in nature, to demonstrate the ongoing paradigm shift of incorporating
patient views in modern biomedical research (see Wilson, 2000). I used the following
questions to guide my literature search:


In patients with the same disease state and undergoing a standard protocol of
treatment for it, why do some have better biomedical (e.g., controlled disease
state as evidenced by laboratory blood chemistry measures) and psychosocial
(e.g., self-reported days of feeling well/sick) outcomes than others?



What are the factors associated with better or worse outcomes?



How have researchers analyzed the relationship between social factors and
medical outcomes?



What have researchers done to address medical outcomes related to social
factors?



What research methods have been used in the past to determine associations
between social parameters and medical outcomes?

The literature search began on June 30, 2014. My strategy included assessing key words
in the Walden University Library Health Sciences Research databases. The databases
searched included MEDLINE with Full Text, CINAHL Plus with Full Text, ProQuest
Nursing & Allied Health Source, PubMed, and Science Direct. Additionally, a Thoreau
multidatabase search was conducted. The keywords used were chronic illness or chronic
disease, well-being, AND genetic disorders; well-being AND primary immune; burden of
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disease AND subcutaneous AND intravenous; bio-psychosocial model; treatment
preferences AND subcutaneous AND intravenous; patient-focused; patient-centered;
patient-reported outcomes; and PIDD.
Then, I narrowed the search to include primarily peer-reviewed articles published
in the years between 2008 and 2017, unless a seminal piece of literature added context to
the review. Because the medical product innovations being studied do not all have
pediatric indications, I excluded articles which focused solely on children. The focus of
the dissertation was a rare genetic medical condition (PIDD) which, with treatment, is
manageable for years and decades like a chronic disease (see Chapel et al., 2014). Thus,
I excluded literature which focused on terminal illnesses. Because PIDD stems from a
biological cause, I also excluded literature focusing on psychological disorders.
I consulted timely nonscholarly works such as transcripts of the FDA’s patientcentered drug development program as an endeavor to add clarity on patient perspectives
(Coplan, Noel, Levitan, Ferguson, & Mussen, 2011). FDA’s patient-centered drug
development program encompassed a series of public meetings, each focused on a
different medical condition. Patients with a given disease spoke about their life with the
condition. Caregivers and individuals representing advocacy organizations spoke about
their life as a caregiver or advocate of someone with the condition. Participants shared
their experiences with medical treatments utilized. Participants also discussed their
perspectives about clinical trials, and future treatment options (FDA, 2015a). I reviewed
transcripts from public meetings held inclusive of the years 2011-2016 for the rare and
genetic diseases which involved a treatment regimen administered via the subcutaneous
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or intravenous routes (FDA, 2017). From the transcripts of polling questions and
discussion points, I honed the idea of including well-being measures into the present
study. I also consulted the websites of advocacy organizations, such as International
Patient Organization for Primary Immunodeficiencies (IPOPI) and Immune Deficiencies
Foundation (IDF), and articles referenced on their websites to elucidate variables for
consideration in the present study. Lastly, I consulted websites such as Clinical
Trials.gov, NIH, FDA, and National Organization for Rare Disorders (NORD).
Theoretical Foundation
The theoretical foundation used in this study was the biopsychosocial model.
According to the tenets of this model, health and illness are not merely biological.
Instead, health and illness involve the whole individual. Thus, the contributions to health
and illness include biological, psychological, and social parameters (Engel, 1980). This
holistic framework includes biological (i.e., organs, organ systems, biochemistry, vital
signs, and physical presentation); psychological (i.e., attitude, behaviors, emotions, and
preferences); and social (i.e., where and with whom one navigates through daily life at
home, at school, at work, at places of worship, relationships, participation) elements
(Engel, 1980). I designed my study to use the biopsychosocial model to relate the
biomedical variables of medical product innovation with the psychosocial variables of
HRQOL and well-being.
Immunoglobulin replacement therapies developed by medical product
manufacturers for PIDD are only approved by FDA once they are demonstrated via
clinical trials with biomedical endpoints to be safe and effective (Melamed et al., 2012).
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The biomedical endpoints include biological measures such as IG blood levels and the
metabolism process, monitoring site of injection and systemic reactions, and measuring
and assessing changes in infection rate (Dashti-Kavidaki et al., 2009; Melamed et al.,
2012). Patients, caregivers, and advocates express their desire for improved treatments.
They serve as agents stimulating medical product manufacturers to support research
aimed at soliciting and evaluating patient feedback regarding satisfaction with current
treatment, and preferences for improvements in treatment offerings (Doward,
Gnanasakthy, & Baker, 2010). FDA regulators seek to inform their regulatory decisionmaking using biomedical endpoints from clinical trials and input from patient-reported
outcomes collected during clinical trials (U.S. Department of Health and Human
Services, 2009). A search of the literature revealed studies on the PIDD population
measuring patient-reported outcomes (see Table 1).

Table 1
Review of Patient-Reported Outcomes Studies on Primary Immune Deficiency Disease
Reference

Objective and
population

Variables

Patient-reported outcomes by
measurement instrument

Results

Bienvenu et al.
(2016)

Patient treatment
satisfaction and quality of
life.

Demographic
Lifestyle
Occupation
Comorbidities
Infections
History of PIDD
History of IGRT
IGRT route/ place of
administration
IG serum level
Patient satisfaction
Quality of Life

Life Quality Index (LQI) factors I,
II, III

Satisfaction with home-based treatment
interference was higher for SCIG than
for IVIG.
Satisfaction with IVIG treatment
interference was higher in a hospital
setting than in a home setting.
There was no difference between route
of administration and place of
administration on patients’ satisfaction
with therapy-related problems.
Satisfaction with therapy setting was
optimal for home-based SCIG.
QOL related to route and place of
administration revealed no statistically
significant differences.

Prospective,
observational cohort
study of 116 PIDD
patients receiving
immune globulin
replacement therapy
(IGRT) took place in
France for 12 months.

Treatment satisfaction with IG
replacement therapy
Treatment interference
Therapy-related problems
Therapy Settings
Short Form-36 (SF-36), v2
Quality of Life

(table continues)
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Reference

Objective and
population

Variables

Patient-reported outcomes by
measurement instrument

Results

Espanol et al.
(2014)

Patient preferences
regarding treatment and
therapy administration.

Current treatment
Route/ place of
administration
Dose frequency
Treatment satisfaction
Treatment-related adverse
events
Impact of PIDD on
HRQOL
Impact of treatment on
HRQOL

Physical and psychosocial health
measures by
12-Item Short Form Health Survey
(SF-12v2)
HRQOL
10-Item Short Form Health Survey
(SF-10v2)

Patients preferred self-administration
versus administration by a healthcare
professional.
Patients also preferred home versus
hospital administration, therapy which
enabled monthly versus weekly or
every two weeks treatment, fewer
needle sticks, and shorter infusion
time.

Lifestyle
PIDD diagnosis
PIDD treatment
Comorbidities
Amounts of anxiety and
depression experienced
and attributed to PIDD
diagnosis

Hamilton Depression Rating Scale
(HAM-D)

On-line multinational
survey completed by 300
patients from 21 different
countries.

Heath,
Lehman,
Saunders, and
Craig (2016)

Depression and anxiety
level experienced by
patients with PIDD and
how much depression and
anxiety they attributed to
their PIDD.
Telephone voluntary
survey was extended to
PIDD patients at a
university division of
pulmonary, allergy, and
immunology in the
United States.

Self-care, usual activities, pain/
discomfort, anxiety/ depression by
EuroQOL five Dimensions

Amount of depression experienced
Amount of depression attributed to
PIDD
Hamilton Anxiety Rating Scale
(HAM-A)
Amount of anxiety experienced
Amount of anxiety attributed to
PIDD

Patients with PIDD had median HAMD scores comparable to the US
population.
Patients receiving IVIG therapy in the
home or in a clinic had significantly
higher HAM-D scores than those
receiving SCIG at home.
Patients who had healthcare
professional administered therapy had
higher HAM-D scores than those who
self-administered.
Higher HAM-D scores were associated
with adverse effects from IGRT.
Patients receiving IVIG attributed
higher amounts of their anxiety to their
diagnosed PIDD compared with those
receiving SCIG.
(table continues)
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Reference

Objective and
population

Variables

Patient-reported outcomes by
measurement instrument

Results

Jorgensen et al.
(2014)

HRQOL in patients with
selective IgA deficiency
(SIgAD) and to determine
factors leading to poor
HRQOL.

Gender
Age
Education
Employment Status

SF-36
Global HRQOL
Self-reported HRQOL
Role-physical
General health
Social functioning
Role-emotional
Mental health

Patients with SIgAD reported lower
global HRQOL than did the control
group of persons with normal immune
globulin levels. The differences were
not statistically significant.

Gender
Age
Race
Employment status
PI diagnosis
Route of administration

Self- or healthcare professional
administration
Frequency of administration
Location of administration
Number of needle sticks per
treatment
Treatment duration
Treatment preference

Patients indicated preferences for
monthly versus weekly administration,
home setting versus doctor’s office/
hospital/ clinic, shorter versus longer
treatment durations, and fewer needle
sticks of IG treatment relative to
alternative choices.

Gender
Age
Race
Education level

Perceived health status

Patients perceived their health as
excellent or very good (30%), good
(31%), or fair, poor, or very poor
(39%).

Icelandic patients with
SIgAD (n=33) were
matched with randomly
selected age and gendermatched Icelandic
controls (n=96) with
normal immune globulin
levels.
Mohamad,
Kilambi, Luo,
Iyer, & LiMcLeod (2012)

To promote patientcentered care by
calculating the relative
importance of immune
globulin treatment
attributes to patients.
Web-enabled choiceformat conjoint survey
was completed by 252
patients.

Seeborg et al.
(2015)

Total of 1526 patients
(61.2%), with PIDD from
across the United States
returned a selfadministered
questionnaire.

(table continues)
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Reference

Objective and
population

Variables

Patient-reported outcomes by
measurement instrument

Results
Perceived health was associated with
age, gender, education level, and
employment status.
Patients with access to IVIG therapy
and specialty care were more likely to
perceive their health as excellent or
very good.

Tabolli et al.
(2014)

HRQOL and
psychological status
among PIDD
(specifically CVID)
patients to compare
immune globulin therapy
administration regimens.
Six-year longitudinal
cohort study followed an
initial 96 patients.

Gender
Age
Duration of disease
Comorbidities

Short Form-36 (SF-36)
General Health Questionnaire
(GHQ-12)
Psychological distress
Depression
Anxiety

HRQOL scores were low, and were
also lower than those reported by
generally healthy people, and by
people with other chronic diseases
(except heart failure).
Female gender and older age was
associated with poorer quality of life.

PGA
Disease clinical severity perception
relative to other patients with the
same disease
(table continues)
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Reference

Objective and
population

Variables

Patient-reported outcomes by
measurement instrument

Results

Vultaggio et al.
(2015)

To evaluate changes in
biomedical and patientreported parameters in
response to a shift from
IVIG to SCIG.

Age
PIDD diagnosis
Treatment route of
administration
Baseline serum trough IgG
levels
Annual rate of severe
bacterial infections
Number of days off school/
work
Days of hospitalization due
to infections
Medication tolerability

Child Health QuestionnaireParental Form 50 (CHQ-PF50)
Physical functioning
Psychosocial functioning
Well-being

Treatment with SCIG did not
significantly improve HRQOL in
patients with PIDD.

The multicenter
prospective observational
study included 50 patients
in Italy with PIDD who
also were concurrently
taking part in a PIDD
medical product clinical
trial monitored for 24
months.

Short Form 36
Role-physical
General health
Vitality
Social function
Role-emotional
Mental health
Life Quality Index
Impact of the IgG treatment on
daily activities
Visual Analogue Scale
Perception of general health

30

31

As noted in Chapter 1, I mention the disability paradox as a secondary framework
to explain possible association of independent and dependent variables. The disability
paradox framework is an explanation for why individuals whom an outside observer
would consider to have low HRQOL based on appearance might self-assess a better
HRQOL, even compared with healthy subjects (Albrecht & Devlieger, 1999;
Fellinghauer et al., 2012).
Biopsychosocial Model
George Engel introduced the biopsychosocial model as a counter to the
biomedical approach toward the practice of medicine. Engel (1977) posited that the
biomedical model was inadequate and reductionist as it reduced the patient to his or her
body parts and biochemical elements. Engel posited that the patient is a whole being that
senses and experiences. The patient is a composite of biological, psychological, and
social systems and sub-systems, none of which exists in isolation from the others. The
biopsychosocial model has been used as a model for patient-physician interaction; and as
a framework for how the physician can view the patient and provide care (Engel, 1977;
Engel, 1980; Haveilka et al., 2009). This framework can be used by medical product
manufacturers and regulatory authorities for how they view the person who will use the
medical products once approved.
Why selected for this study? I developed the logic model presented in Figure 1
to show how elements of the biopsychosocial model related to the variables under study
in this dissertation. The biopsychosocial model includes biomedical inputs and
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psychosocial inputs. Biomedical inputs include biochemical effects of the PIDD disease
state and of immunoglobulin replacement therapy (e.g., immunoglobulin levels in the
blood, vital signs, and infection), or how patients reported that they felt (e.g., malaise).
These dependent variables are represented but greyed out in the logic model, because
they are not the focus of this study. Psychosocial inputs include the patient-reported
outcome dependent variables of HRQOL, and well-being. These are shown as green in
the logic model and these are the focus of this study. The intervention is medical product
innovation because of patient treatment preference inputs and biomedical inputs. The
outcome of the intervention would hopefully be a change in patient-reported outcomes of
HRQOL and well-being, for the better, along with maintained or improved clinical
benefits to the patient.
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Bio-psychosocial Model

Framework

Inputs

Biomedical
(dependent variable)
e.g. IG trough levels,
Infections

Intervention

Outcome

Disability
Paradox

Patient-Reported Outcomes
(dependent variable)
e.g. Health-related quality of
life, Well-being

Medical Product Innovation from Patient
Treatment Preferences
(independent variable)
e.g. infusion time, # of needle sticks sticks

Improve
Patient-Reported
Outcomes, Maintain/
improve biomedical
benefits

Figure 1. Logic model.
Chronic disease defies the biomedical concept of a malfunctioning body which
can be restored to function via purely medical or physiological intervention (i.e. if blood
pressure is too low, position the body with head raised and feet lowered and administer a
medical product which makes the blood vessels contract, and if blood pressure is too
high, administer medications to lower it) because chronic disease has no cure. Chronic
disease extends beyond the local physiological parameters of the body and it encroaches
into life by having impact on the social (e.g. engagements, making plans, going out, and
playing with children), and practical (e.g. being able to work, manage a household, selfcare, and hobbies) aspects of life (Kalra, Gupta, & Unnikrishnan, 2016).
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Literature Review of Studies Which Used the Biopsychosocial Model
None of the PIDD articles located in the literature search specifically named the
biopsychosocial model. However, the literature demonstrates that the model has been
used to explain the relationships of independent and dependent variables for other chronic
disease states, and in some cases for rare diseases. A summary of that literature is shown
in Table 2. Elliott and Richardson (2014) studied the biopsychosocial model in persons
with epilepsy. An outside observer aligned with the biomedical model might intuit that
the greatest improvement to HRQOL for persons with epilepsy is to have few or no
seizures. Thus, any medical products which could achieve few or no seizures, along with
fewer side effects, would also improve HRQOL. However, persons with epilepsy have
psychosocial manifestations of epilepsy, such as a greater tendency toward depression
and anxiety which impact ability to attend to requirements of work, school, and social
relationships (Elliott & Richardson, 2014). Elliott and Richardson (2014) argued that due
to a biomedical focus, the psychosocial aspects of epilepsy generally remain untreated.
The researchers established independent variables aligned with the biopsychosocial
model; namely, biomedical (e.g. age, gender, comorbidities, and number of doctor visits);
psychological (e.g. diagnosed depression and/ or anxiety, and number of visits to mental
health professionals); social (e.g. educational attainment, annual income, marital status,
and community belonging). The dependent variables were self-rating of health and
mental health status, and satisfaction with life. Both the independent and dependent
variables were organized from the Canadian Community Health Survey. The researcher
performed correlational analysis on these secondary data and found that, compared to the
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biomedical model, the biopsychosocial model explained more of the variance in QOL,
where Whole Set Correlation R2 = 24.8% for the biomedical model and 55.0% for the
biopsychosocial model, respectively. Additionally, the researchers evaluated biomedical,
psychological, and social elements individually and found that the psychological element
(Partial Set Correlation (PSC) R2 = 30.4%), and the social element (PSC R2 = 26.8%)
explained more of the variance in QOL than the biomedical element alone (PSC R2=
14.3%). Thus, the authors concluded that the biomedical element such as controlling
seizures is important; however, it is not the only element contributing to HRQOL.
Further, the authors called for a patient-centered approach which also brings
psychological and social practitioners into holistic treatment regimens for individuals
with epilepsy. Kalra, Gupta, and Unnikrishnan (2016) argued the value of the
biopsychosocial model in terms of availability of insulin preparations available to
patients. When the biomedical requirements of, say, blood glucose and hemoglobin A1c
are met, the patient and their physician could select an insulin therapy regimen which fits
into that individual patient’s psychological preferences (such as injection frequency and
timing, meal frequency and size, ability to self-inject, and glucose monitoring), and social
preferences (such as lifestyle, infusion location which provides privacy, and work
schedule). The authors noted that soliciting and implementing patient, caregiver, and
advocate treatment preferences along with biomedical measures, is essential for longterm disease management (Kalra, 2014; Kalra et al., 2016).
Baranyi et al. (2013) used the biopsychosocial framework to understand social
and psychological differences between patients who became depressed during interferon
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alpha treatment for hepatitis C, and those who did not as a way of predicting who would
develop depression; and, therefore, to develop preventive measures for such patients (see
Table 2). Baranyi et al. (2013) included a social context (i.e. social support) and set out
to measure changes in HRQOL, life satisfaction, and cognitive ability via validated
questionnaire.

Table 2
Use of Biopsychosocial Model in Literature and How These Studies Compare to PIDD
Reference
Baranyi et al. (2013)

Disease state
Hepatitis C

Comparison with literature on PIDD
Used the biopsychosocial framework to understand social and
psychological differences between patients who became
depressed during interferon alpha treatment for hepatitis C and
those who did not. Like IGRT, interferon treatment for
hepatitis C is administered by subcutaneous injection.
Adherence to a medical product injection regimen is necessary
for viral reduction (Ward & Kugelmas, 2005).

Lasker, Sogolow, Short, and Sass
(2011)

Organ transplant

Used the biopsychosocial model to select HRQOL variables
and assess the demographic, biomedical, psychological, and
sociological factors the researchers believed related to quality
of life. Lasker et al. determined whether those variables
differed before and after transplant; and also determined which
variables were most important.

Verderese, Graham, HolderMcShane, Harnett, and Barton
(1993)

Gaucher’s disease

Measured subjective and objective symptom relief in response
to enzyme replacement therapy in patients with Gaucher’s
Disease. Like PIDD, Gaucher’s disease is a rare genetic
disorder mitigated by outpatient replacement therapy
administered intravenously two to four times per month.
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Criticism of the Biopsychosocial Model. Criticisms of the biopsychosocial
model include that the model does not stand on its own, but is instead an extension of the
biomedical model with psychological and social factors added on; constructs are not well
defined; and the model does not explain the origin of disease (Haveilka et al., 2009).
Primary Immune Deficiency Disease
The prevalence of infectious diseases in the early part of the twentieth century
masked PIDD. As scientific progress in medicine and public health interventions brought
infectious diseases under control, medical cases of chronic diseases became more
prevalent. Cases of PIDD also became observable to the medical community due to the
manifestation of unusual and severe infectious diseases which could be readily treated for
individuals with an intact immune system (Chapel et al., 2014; Costa-Carvalho et al.,
2014). Though there are several types of treatment available for PIDD (e. g. blood stem
cell transplant, antibiotics therapy, or gene therapy), the mainstay treatment is immune
globulin G (IgG) replacement therapy; referred to throughout this dissertation as IGRT
(Chapel et al., 2014; Dashti-Khavidaki et al., 2009). Genetic defects of the immune
system results in defective cells, antibodies, and / or complement. Immunity resides in
the bone marrow and in the blood. As such, the immune system is spread throughout the
body. Thus, a defect in a gene coding for an immunity cell, antibody, or the complement
components has implications throughout the body (Costa-Carvalho et al., 2014).
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The Role of the Patient
Management of PIDD is complex in that it involves a regimen of aseptic medicine
transfer into IV bags and/ or syringes, injection site cleansing, and medication injection
into the intravascular system. Management of PIDD is also burdensome as it involves
making time to visit an infusion clinic to receive medication, or making room in the home
for supplies and time in one’s schedule to administer therapy (Melamed et al., 2012).
However, adherence to the infusion routine is essential for warding off infection
(Bienvenu et al., 2016). IDF is a patient organization providing education, advocacy,
research opportunities, and outreach to and on behalf of people with primary immune
deficiency disease (IDF, n. d.). IDF is a key voice in the United States through which
researchers, regulatory agencies, and medical products manufacturers can understand the
needs of the patients with PIDD.
The Role of the FDA
The FDA, like other ministries of health around the world, protects and promotes
public health via regulation provided to manufacturers of medical products. The premise
is regulatory oversight will result in safe and effective medical products which will
produce positive outcomes for patients. Yet, people with the same disease state and
undergoing the same treatment for it have varying experiences and outcomes (Wilson and
Cleary, 1995).
Through the Patient-Focused Drug Development initiative, FDA officers are
examining burden of disease, treatment preferences, and ways to improve health
outcomes by engaging patients, caregivers, and advocacy organizations in dialog through
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a series of meetings, each covering a different disease state (Lejbkowicz, Caspi, & Miller,
2012; Muhlbacher, Juhnke, Beyer, & Garner, 2016). FDA’s responsibility is to ensure
that the benefits of drugs outweigh the risks, understand how patients view benefits and
risks of treatments, and guide researchers, via the regulatory process, to appropriate end
points to measure how well these drugs are working (FDA, 2015a).
The Role of the Medical Product Manufacturers
Immune globulin G is a highly purified plasma protein. Manufacturers produce
IgG by purifying plasma collected from donors. The proprietary manufacturing process
each manufacturer uses includes fractionation steps, viral deactivation, excipients
addition, and pH and temperature adjustments (Chapel et al., 2014). For initial approval
by FDA, manufactures of IGRT are responsible for ensuring the key biomedical factors
of safety (e.g. no viral transmission from the IG to patient), efficacy (e.g. reduced
infections), and tolerability (e.g. few or no adverse reactions) are confirmed in humans
via clinical trial (Chapel et al., 2014). After initial approval by FDA, manufacturing
status, changes, safety reports, and post-marketing clinical and non-clinical commitments
or requirements are each reported to FDA on various frequencies such as batch-to-batch,
quarterly, and annually.
Medical products manufacturers have incorporated patient perspectives into
therapy improvements with the aim of improving treatment satisfaction and quality of
life, and the FDA has approved these therapies.
The first such improvement was developing therapy alternatives enabling patients
to move from intravenous administration in a clinical setting to subcutaneous
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administration in the home. Research showed improvements in HRQOL (Garduff &
Nicoloay, 2006). The next medical product innovation, in response to patient expression,
was development of therapies with reduction in the number of needle sticks and shorter
infusion times while maintaining self-infusion at home (Espanol et al., (2014).
Preliminary analysis suggested that these changes to medical product innovation would
result in reduced burden; therefore, improved quality of life (Ponsford et al. 2015;
Wasserman, 2014).
Treatment Options
The three routes of IGRT administration include needle injections into the muscle,
veins, or under the skin. Intramuscular injection (IMIG) is a rarely used route of
administration. In a study of patients receiving IVIG, causes of adverse reactions (e.g.
fever and chills) included infection, infusion reactions, infusing too rapidly, switching
medications, first infusion, and a long-time interval between injections (Dashti-Khavidaki
et al., 2009). The first IGRT was delivered subcutaneously in 1952 and was thereafter
delivered intramuscularly until 1980. From 1980 to the present IVIG has been prominent
and as recently as 1991, SCIG has begun to make a resurgence (Haddad et al., 2012).
Researchers evaluating the biomedical effects of SCIG noted systemic adverse events
were reduced while the effects (e.g. burning, itching, and swelling) were localized to the
site of injection (Haddad et al., 2012; Melamed et al., 2012).
Burden of Treatment
Hirsch, Walker, Chang, and Lyness (2012) studied chronic diseases in adults aged
65 and older and analyzed the extent to which anxiety, as a result of the burden of
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medical illness, is reduced by the presence of optimism and increased by the presence of
pessimism. The researchers’ hypothesis was realized by the results and this led to their
suggestion to implement moderating factors such as training patients to have positive
thoughts and to foster meaningful relationships, and developing clinical health
interventions which shift the patient’s frame of mental reference to a more optimistic
viewpoint (Hirsch et al., 2012).
Verderese et al. (1993) measured subjective and objective symptom relief in
response to enzyme replacement therapy in patients with Gaucher’s Disease. Like PIDD,
Gaucher’s disease is a rare genetic disorder (where glucocerebrosidase enzyme is lacking
resulting in the systemic buildup of the lipid glucocerebroside inside macrophage white
blood cells and organs such as the spleen, liver, and bone marrow) which is mitigated by
outpatient replacement therapy administered intravenously. After each enzyme
replacement treatment, Verderese et al. (1993) recorded subjective patient perceptions on
reduction of bruising (measured by increased platelet counts), chronic fatigue (measured
by increased hemoglobin concentration), and gastrointestinal protrusion (measured by
reduced abdomen size) and found the subjective perception of symptom relief often
preceded the laboratory measurement of the corresponding parameter. Additionally, selfconcept, self-esteem, self-image, and mood were reported to have improved due to
patients’ having more energy and reduced abdominal size, leading to more confidence in
the social and relationships arena.
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Patient-Focused Drug Development and Patient-Centered Treatments
As described in the FDA Prescription Drug User Fee Act Patient-Focused Drug
Development (2013) announcement in the Federal Register, FDA personnel initiated a
series of public meetings under its Patient-Focused Drug Development initiative. Each
meeting focused on a specific disease, with involved FDA staff, patients, caregivers, and
advocacy organizations. The FDA personnel used mixed-methods research
methodology and gathered information through questionnaires, polls, written comments,
and focus group discussions regarding daily life, lived experience with the disease, the
symptoms of greatest impact, current medical and non-medical treatment regimens in
use, and opinions about clinical trials. Theoretically, this patient-centered approach
would be an input to the regulatory guidance provided to medical product manufacturers
for new and already commercialized products as well as to the regulatory decisionmaking used by the Agency for initial approval (FDA, 2015a).
Patient reported outcomes are increasingly solicited via surveys presented to
participants in clinical studies intended to show drug safety and efficacy. However,
results may not be reflective of the general population who will use the drug upon its
commercialization due to the selection criteria used for clinical trial participation.
Fleurence et al. (2013) argued the importance of including the patient perspective into
clinical studies. The researchers used as examples Alzheimer’s dementia and a
comparison of two heart surgery interventions. In the former, the clinical endpoint would
typically be changes representing improved cognitive ability. However, patient
preference could be for improvement in capacity to function in activities of daily life. In
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the latter example, the clinical endpoint could be decreased complications and increased
longevity. However, patient preference was for relief of chest pain (Fleurence et al.,
2013). Related to PIDD, immunoglobulin replacement therapy safety and efficacy
clinical endpoints typically are measured by IgG trough levels, change in the number and
types of infections, change in the number and types of infections requiring
hospitalization, and site of injection issues (Dashti-Khavidaki et al., 2009). However,
one of the challenges to drawing conclusions regarding patient preferences compared to
the clinical endpoints measured via laboratory analysis and/ or mathematical calculation
is they are inherently subjective and require interpretation and translation to objective
measures. Conjoint analysis and Best-Worst Scaling (BWS) are two statistical methods
for elucidating patient medical treatment preferences and moving from qualitative to
quantitative. This enables medical product manufacturers to have a quantitative basis for
assessing patient-reported endpoints and also developing next generation products.
Additionally, such measures of patient preferences are useful to regulators in their review
of new product applications and ongoing surveillance of commercial medical products
(Johnson & Zhou, 2016; Morel, et al., 2016). Conjoint analysis has its origin in
consumer research aimed at understanding preferences for various attributes of a product
offering (Kinter, Prior, Carswell, & Bridges, 2012). In the health care setting, conjoint
analysis and BWS can be used to help medical product manufacturers, and the FDA
understand the relative importance of treatment attributes, and risk to benefit tradeoffs
acceptable to patients and/ or caregivers (Kinter et al., 2012). Mohamed et al. (2012)
utilized conjoint analysis to examine treatment preferences of 252 patients with PIDD
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and 66 parents, all in the United States, regarding treatment provider (self or healthcare
professional), frequency (every other week or weekly), location (home or clinic), needle
sticks (four or one), and treatment duration (6 hours or 2 hours). Treatment preferences
were selected based on a qualitative pre-test with a sample of nine patients and parents
using open-ended interview questions. In the study, route of administration was
predominately IVIG (59.9%) versus SCIG (41.1%). Both patients and parents preferred a
home setting, monthly infusions, fewer needle sticks, and shorter duration. In terms of
preference for treatment, both patients and parents considered least important whether the
patient self-infused treatment or a healthcare provider administered the treatment. For
patients, location was the most important and for parents, frequency was most important.
Regarding relative importance to patients of the individual therapy attributes and tradeoffs, with increased treatment frequency, fewer needle sticks and shorter duration became
more important. Espanol et al. (2014) elucidated PIDD treatment preferences from 216
patients and 84 caregivers via a multinational online survey using conjoint analysis. In
contrast with Mohamed et al. (2012), route of administration (e.g. IVIG, SCIG, and
other) was a distinct category along with patients and caregivers (referred to as parents by
Mohamed et al.) and was analyzed as such by Espanol et al. (2014). Respondents
represented 21 countries on the continents of Africa, Asia, Australia (including New
Zealand), Europe, North America (excluding the US), and South America. Intravenous
(53%) and subcutaneous routes (45%) of administration were represented. Patients on
IVIG received therapy an average of every 23 days in a clinical (75%) setting or at home
(15%) while 94% of the patients on SCIG had therapy in the home an average of every
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six days. Patients and caregivers were asked to respond to the following categories of
preferences: (a) self-administration versus administration by a health professional; (b)
monthly, every-other weekly, or weekly treatment frequency; (c) home or clinical
treatment location; (d) one, two, or four needle sticks per treatment; and (e) two, four, or
six-hour therapy duration. Across the IVIG and SCIG routes of administration, both
patients and caregivers preferred monthly treatments, a home environment, one or two
needle sticks, and two-hour therapy duration. SCIG patients and caregivers significantly
preferred self-administration while the preference for IVIG among patients and
caregivers was not statistically significant. Both sets of authors indicated the importance
of assessing PIDD patient and caregiver preferences and representing these preferences in
treatment offerings to fulfill unmet needs in terms of HRQOL. Interestingly, both studies
were supported by medical product manufacturers, and this suggests an understanding
that gauging patient and caregiver preferences is an important input to their decisions
about next generation therapies. Hollin, Paey, and Bridges (2015) further illustrated the
usefulness of quantifying patient treatment preference. This study was initiated by
caregivers to children with Duchene Muscular Dystrophy. The patient advocacy
organization called Parent Project Muscular Dystrophy (PPMD) engaged the Duchene
Muscular Dystrophy community in gathering treatment preferences and, with FDA’s
blessing, modeled their approach after FDA’s Patient-Focused Drug Development
initiative, with the exception that PPMD used conjoint analysis and best-worst scaling
(BWS) to quantitate treatment preferences. Hollin et al. (2015) compared two methods
of quantitating patient preferences to demonstrate the reliability of the survey method
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used to collect preferences. Their study was also intended to provide evidence the
methodology can be useful for regulatory decision-making in terms of medical product
and treatment risk-to-benefit and tradeoffs patients and caregivers are willing to make
(Hollin, Paey, & Bridges, 2015). This study underscores the role of patients and
caregivers with their advocacy organizations, medical products manufacturers, and FDA
in facilitating the provision of patient-centered treatments (Hollin et al., 2015).
Patient-Reported Outcomes: HRQOL and Well-being
As discussed, one of the goals for measuring patient preferences for treatment is
to demonstrate treatment tradeoffs and risk-to-benefit of treatment attributes patients and
caregivers are willing to make (Hollin et al., 2015). However, another goal for measuring
patient preferences for treatment is to ultimately improve patient HRQOL and well-being.
As with other diseases, researchers studying patients with PIDD have argued for the
development of a HRQOL instrument specific to overall primary immune deficiency as
well as specific variants of the disease (Quinti et al., 2016).
Studies located for this review measured HRQOL and well-being associated with
patient satisfaction with current treatment for PIDD over time; changes in treatment
regimen; and aspects of treatment which change perceived health. Kobrynski (2012)
reviewed nine studies which compared route of administration and location of
administration (home versus hospital). The studies took place in Europe (three each in
Sweden and Germany, and one in Norway and Denmark) and in North America (USA
and Canada), from 1995 to 2011. Seven studies examined changes in HRQOL and wellbeing comparing immunoglobulin delivery by the intravenous route of administration in a
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clinical setting (e.g. hospital or clinic) to immunoglobulin delivery by the subcutaneous
route of administration in a home setting. Generally, study results revealed treatment
satisfaction with SCIG as measured via the Life Quality Index (LQI) instrument. Other
improved HRQOL measures included general health perception, family activities, and
general health as measured by Short Form-36 (SF-36) and Child Health QuestionnaireParent Form 50 (CHQ-PF50). Among patients receiving IVIG, one study showed some
viewed SCIG in the home as inconvenient. One study comparing SCIG in the hospital/
clinic versus SCIG in the home revealed patient satisfaction and feeling of independence
with home infusions of SCIG. Finally, authors of one study compared treatment
regimens which could reduce home-based SCIG infusion times and found high
satisfaction with rapid infusion.
Jiang et al. (2015) also reviewed the literature regarding HRQOL in patients with
PIDD. The researchers focused on treatment regimen satisfaction (i.e. route and location
of administration) measured via commonly used survey instruments (see Table 1). Jiang
et al. also included studies which made comparisons between patients with PIDD and
healthy study subjects, and studies which compared patients with PIDD to patients with
other chronic diseases. Factors associated with poorer HRQOL included comorbidities,
employment status, stress, multiple infections, and PIDD diagnosis delay. Other factors
associated with improved HRQOL included home-based therapy; treatment comfort,
flexibility, convenience, and independence; shorter treatment duration and less impact/
disruption to daily activities (e.g. school/ work, and social); and satisfactory
immunoglobulin trough levels (Jiang, et al., 2015; Vultaggio et al., 2015). Espanol et al.
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(2014) showed the majority of patients with PIDD (76%, n=300) were pleased with their
current treatment; however, those receiving SCIG (83%) were more pleased compared to
those receiving IVIG (69%). Relating SCIG and IVIG treatment to HRQOL, as assessed
by the EQ-5D, measures of anxiety, depression, mobility, routine activity performance,
pain, and self-care revealed there was no difference in HRQOL (71.8% and 71.9%,
respectively). Overall, HRQOL was found to be poorer in patients with the common
variable immune deficiency form of PIDD than in the US population as measured by EQ5D and SF-36 instruments (Espanol et al., 2014; Tabolli et al., 2014). In contrast,
assessment of HRQOL by SF-36 in PIDD patients with a deficiency of immune globulin
A (n=32) compared with age and gender matched controls (n=63) revealed no
statistically significant difference (Jorgensen et al., 2013). Likewise, a study focused
specifically on HRQOL, anxiety and depression in patients with PIDD (n=33) as
measured by HAM-D and HAM-A found that levels were similar to the general US
population.
The synthesis of the abovementioned studies reveals that HRQOL has been
measured as a dependent variable according to patient preference for treatment, such as
route of administration (intravenous versus subcutaneous), place of administration
(clinical setting versus home environment), and infusion duration using a standard SCIG
route versus a newly innovated enzyme-facilitated SCIG route. The HRQOL measures
were assessed using various commonly used instruments. Additionally, the literature
revealed sources of variables leading to higher or lower HRQOL scores with moderating
or confounding variables. The literature has not yet been expanded to present the
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changes in HRQOL and well-being as dependent variables to recent medical product
innovations allowing for fewer needle sticks and offering shorter infusion duration using
the PROMIS-29 instrument in a population of patients with PIDD. This is the area where
my dissertation can begin to close this gap.
PROMIS Instrument
The PROMIS instrument is a set of standardized and validated questionnaire
items used for measuring QOL. Developed under the National Institutes of Health’s
Roadmap Initiative, PROMIS can be utilized across a number of chronic disease states,
including for genetic diseases (Cohen & Biesecker, 2010).
Summary and Conclusions
I introduced the literary basis for this study of mean changes in HRQOL and wellbeing for patients with PIDD who use medical products innovated with consideration of
patient preferences for treatment; specifically, the number of needle sticks and infusion
time. Additionally, I presented a literary basis for use of the biopsychosocial framework
to explain the relationship between the dependent and independent variables. In the
following chapter, I present the research questions and further elucidate study variables
and how these variables were operationalized.
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Chapter 3: Research Method
Introduction
The purpose of this study was to examine whether the incorporation of patient
preferences for treatment into medical product innovation results in improved HRQOL
and well-being for patients with PIDD. Use of statistical tools such as conjoint analysis
to quantify patient preferences for treatment provides medical products manufacturers
with data for their development of next-generation products aimed at improving patient
experience as measured by HRQOL and well-being scales (Mohamed et al., 2012; Morel
et al., 2016). Patient preferences also inform FDA leaders in their regulatory decisionmaking. For example, FDA leaders consider the biomedical elements of a nextgeneration medical product in terms of safety and efficacy of metabolism once in the
body as well as the psychosocial elements related to the daily life of patients and
enhancing quality and well-being (Johnson & Zhou, 2016).
Through the literature review process, I learned the following: (a) HRQOL and
well-being have been measured for patients with PIDD; (b) patients with PIDD have been
queried regarding treatment preferences, and some of these preferences have been
measured using standard instruments which measure HRQOL, such as SF-36; and (c)
manufacturers of medical products have developed therapies to align with patient
preferences for treatment. As discussed in Chapter 1, type 2 diabetes is one mainstream
example where medical product manufacturers have innovated a variety of therapies in
response to patient preferences for treatment in terms of dosing flexibility, dosing with or
without food, and number of doses needed per week (“How Trulicity Can Help,” 2017;
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Schroeder, & Dougherty, 2012). Similarly, manufacturers of medical products have
innovated a variety of therapies for patients with PIDD. The gap that I observed in
reviewing the literature regarding PIDD is that there has not yet been a study showing
that patient treatment preferences for fewer needle sticks and shorter infusion time
translated into improved HRQOL and well-being, as measured by the PROMIS-29
instrument, for patients taking medical products innovated per these preferences.
I divided this chapter into sections which cover the research design and rationale,
the PIDD population studied, study design, determination of sampling size and methods
for procuring a sample, and data analysis methods. Additionally, I discuss protection of
human subjects, data handling, and threats to internal and external validity. The
reliability and validity of the PROMIS survey instrument were discussed in Chapter 2.
Research Design and Rationale
Using a cross-sectional study design, I sought to examine whether patient
preferences for fewer needle sticks and shorter infusion time translated into differences in
HRQOL and well-being for patients with PIDD who were using medical products
innovated according to those preferences. The independent variables were needle sticks
and infusion time. Based on the medical product each patient reported using at the time
of data collection, I assigned patients into two categories: those who used the medical
product innovated for each of the independent variables under study and those who did
not (see Table 3). Thus, patients who reported using a medical product innovated to need
fewer needle sticks were compared to those patients who reported using a medical
product which does not entail fewer needle sticks. Likewise, patients who reported using
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medical products which allow for a shorter infusion time were compared to those patients
who reported using medical products which do not entail a shorter infusion time. I
compared the mean PROMIS-29 scores for HRQOL (e.g., anxiety and depression) and
well-being (e.g., ability to participate in social roles/activities) for each patient group.
I used PROMIS instrument measures for understanding well-being and HRQOL.
The proxy measure for well-being was “Ability to Participate in Social Roles/Activities”
while the proxy measures for HRQOL were “Anxiety” and “Depression”; all of these
PROMIS measures were the dependent variables (Barile et al., 2013; HealthyPeople.gov,
2017). The potential confounding variables of age, gender, education level, and
employment status related to HRQOL have been studied in patients with PIDD (see
Seeborg et al., 2015; Tabolli et al., 2014). In this study, age, median household income,
and gender were part of the secondary dataset I used and were, therefore, available for
analysis.
Methodology
Population
The population data used for this research included all patients who had a
confirmed diagnosis of PIDD and who were using IGRT. Additional inclusion criteria
included patients who gave consent and completed the PROMIS-29 instrument via the
USIDNET (collaboration between the NIH and the IDF) and who also had medical
information on file in IDF’s patient registry. As of October 2017, the total population for
inclusion consideration was 162 patients. Any patient who met the criteria for
completion of the PROMIS-29 instrument was considered for the study.
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Sampling and Sampling Procedures
I received a written invitation from IDF to submit a query to USIDNET (see
Appendix A) after I had contacted IDF regarding any QOL data they might have from
patients with PIDD. The query was generated based on my response to questions from
which I could select categories of information. The query template also included fields
into which I could write provide additional information or make requests. My query
served as the basis for establishing the study population (see Appendix B).
When selecting a sample, two of the considerations were effects size and also the
alpha and beta levels. The effects size (Cohen’s d), which I obtained from the literature
(see Bienvenu et al., 2016) and also from informal calculations of standard deviations of
independent variables, is 0.16. This effect size is small (Cohen, 1988). Regarding alpha
and beta levels, these should be selected so that the sample size is large enough to have
enough power to detect a statistically significant difference and so that the null
hypothesis is not falsely rejected or maintained (Banerjee, Chitnis, Jadhav, Bhawalkar, &
Chaudhury, 2009). I selected an alpha of 0.05 and a beta of 0.20 to establish power equal
to 80%.
I used the entire population of individuals meeting the inclusion criteria. IDF, via
USIDNET, solicits additional patient participation every 6 months, in spring and fall (M.
Goldsmith, personal communication, February 9, 2017). After I obtained Walden
University IRB approval, I e-mailed IDF staffers and requested that they run my query
again to potentially gain more participants. I also submitted a second query for patients
who had not completed the PROMIS-29 survey. The purpose of this query was to draw
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comparisons on attributes common between those who did and those who did not
complete the PROMIS-29 survey in order to potentially generalize HRQOL and wellbeing results. Permission to submit a query and use resultant information is located in
Appendix A.
Research Questions and Hypotheses
The overarching question was whether addressing patient preferences for
treatment through medical product innovation resulted in better outcomes from a
psychosocial perspective, and whether any of these outcomes were also influenced by
gender, median household income, or age. MacKinnon and Luecken (2008) described
various types of other variables according to their relationship to the independent and/or
dependent variable. The authors mentioned that mediating variables are caused by the
independent variable and cause the dependent variable; and moderating variables as those
which aid in understanding the circumstances for when the independent and dependent
variables are related (MacKinnon & Luecken, 2008). MacKinnon and Luecken (2008)
also defined a confounding variable as one which is related to both the independent and
dependent variables and thus changes the relationship between the two; and covariates,
which can be related to the independent and / or the dependent variable but do not change
the relationship. In my study, consideration of gender, age, and median household
income could explain the circumstances under which patients have a greater sense of
well-being and HRQOL when using a medical product innovated according to a given
patient-reported outcome. The variables might also be related to selection of medical
product. Thus, gender, age, and median household income could be moderating or
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confounding variables. There were two additional potential confounding variables over
which I thought I might have control since data fields were available by query within the
secondary data available from IDF. The first variable related to active disease present at
the time the patient completed the PROMIS-29 assessment. Bienvenu et al. (2016) found
that patients with active disease had lower HRQOL scores compared to those without.
Thus, via the literature, active disease showed a link to my dependent variables which
measure HRQOL. Results could be confounded if levels of active disease differ across
my independent variable (patient preference for treatment). The second confounding
variable potentially was treatment-related symptoms or adverse events associated with
the route of administration (SCIG or IVIG) and influence on HRQOL (Espanol et al.,
2014). Administration via the subcutaneous route tends to produce localized effects such
as swelling, redness, and pain around the site(s) of needle insertion. Administration via
the intravenous route tends to result in systemic effects such as fever and malaise
(Kobrynski, 2012). However, both routes of administration can produce local and/or
systemic effects. When I compared dependent variables for HRQOL for infusion time,
results might have been confounded by treatment-related symptoms and/ or adverse
events because the SCIG group was directly compared to the IVIG group. The groups
were not homogenous across the two routes of administration. However, in practice,
patients move across the routes of administration according to their individual needs,
preferences, and doctors’ recommendation (Espanol, et al., 2014, Kobrynski, 2012). For
those patients who moved across therapies and routes of administration, I used the
medical product the patients were using at the time they took the PROMIS-29 survey.
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Table 3 shows the link between patient preferences for treatment and medical product
innovation that were assessed.
Table 3
Operationalization of Variables
Patient preference for treatment, with
literature reference

Medical Product Innovation Comparison
Groupsa

Fewer needle sticks

IVIG

10% SCIG

Kobrynski (2012, p. 285)

Enzyme-facilitated IG

20% SCIG

Shorter infusion time

20% SCIG

IVIG

Espanol et al., (2014, p. 622)

Enzyme-facilitated IG

Melamed et al., (2012, p. 453)
Ponsford et al., (2015, p. 305-307)
a

The mean for each dependent variable was compared.
Data Analysis Plan
The statistical methods originally planned for addressing the research questions

included two-tailed t-tests for independent samples, and possibly correlation and
regression analyses (logistic regression for categorical variables, and multiple regression
for quantitative variables), and ANCOVA in order to test the difference between means
(see Table 3) while controlling for age, gender and median household income. The
assumptions were that the data are homogenous and normally distributed; thus, these
attributes could be tested using parametric statistics.
Research Question 1: Is there a difference in the well-being proxy PROMIS score
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who
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report using medical products innovated to offer therapeutic dosing with one needle stick
every 3 or 4 weeks compared to those who report using medical products innovated to
offer therapeutic dosing with more than one needle stick every 3 or 4 weeks?
H01: The mean differences are not statistically significant.
Ha1: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 2: Is there a difference in the HRQOL proxy PROMIS score
for “Anxiety” between patients with PIDD who report using medical products innovated
to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared to those
who report using medical products innovated to offer therapeutic dosing with more than
one needle stick every 3 or 4 weeks?
H02: The mean differences are not statistically significant.
Ha2: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 3: Is there a difference in the HRQOL proxy PROMIS score
for “Depression” between patients with PIDD who report using medical products
innovated to offer therapeutic dosing with one needle stick every 3 or 4 weeks compared
to those who report using medical products innovated to offer therapeutic dosing with
more than one needle stick every 3 or 4 weeks?
H03: The mean differences are not statistically significant.
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Ha3: The mean differences are statistically significant.
The independent variable was needle sticks, and the dependent variable was PROMIS
score (Likert scale mean).
Research Question 4: Is there a difference in the well-being proxy PROMIS score
for “Ability to Participate in Social Roles/Activities” between patients with PIDD who
report using medical products innovated for shorter infusion time compared to those who
report using medical products not innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford et al.,
2015).
H04: The mean differences are not statistically significant.
Ha4: The mean differences are statistically significant.
The independent variable was infusion time duration, and the dependent variable was
PROMIS score (Likert scale mean).
Research Question 5: Is there a difference in the HRQOL proxy PROMIS score
for “Anxiety” between patients with PIDD who report using medical products innovated
for shorter infusion time compared to those who report using medical products not
innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
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to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al.,
2015).
H05: The mean differences are not statistically significant.
Ha5: The mean differences are statistically significant.
The independent variable was infusion time duration, and the dependent variable was
PROMIS score (Likert scale mean).
Research Question 6: Is there a difference in the HRQOL proxy PROMIS score
for “Depression” between patients with PIDD who report using medical products
innovated for shorter infusion time compared to those who report using medical products
not innovated for shorter infusion time?
Interpretation: Because infusion time depends on patient tolerance irrespective of
product innovation, for this study shorter infusion time was defined as less than or equal
to 4 hours and longer infusion time was defined as greater than 4 hours (Ponsford, et al.,
2015).
H06: The mean differences are not statistically significant.
Ha6: The mean differences are statistically significant.
The independent variable was infusion time duration, and dependent variable was
PROMIS score (Likert scale mean).
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Table 4
List of Variables
Variable

Description

Variable
Type

Code

Medical product promotional or
label claim for the number of
injection sites per dosing
frequency

Categorical

0 = 1 needle stick
per 3-4 weeks
1 = 2 or more needle
sticks per 3-4 weeks

Independent
Needle sticks

Infusion
Duration

Medical product promotional or Categorical
label claim for time per infusion

0 = infusion time
less than or equal to
4 hours
1 = infusion time
greater than 4 hours

Dependent
A domain in the PROMIS-29
validated instrument in this
study used as a proxy for
HRQOL
A domain in the PROMIS-29
validated instrument in this
study used as a proxy for
HRQOL
A domain in the PROMIS-29
validated instrument in this
study used as a proxy for wellbeing

Continuous

XX

Continuous

XX

Continuous

XX

Age
Gender

Patient reported age in years
Patient reported gender

Median
household
income

Median income in US dollars
for the zip code reported by the
patient

Continuous
XX
Dichotomous 0 = male
1 = female
Continuous
XX

PROMIS-29:
Anxiety

PROMIS-29:
Depression

PROMIS-29:
Ability to
participate in
social roles/
activities
Moderating
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Instrumentation
PROMIS-29 is a general instrument intended for persons aged 18 years and older.
The instrument asks four questions from each of seven domains (ability to participate in
social roles and activities, anxiety, depression, fatigue, pain interference, physical
function, sleep disturbance) and one question on a pain intensity scale. Except for
physical function, the domains have a time element and ask for a response based on the
past seven days. For each question within a domain, the participant can select a value
from 1-4. Thus, the lowest score in any singular domain is 4, and the highest score is 20
from the responses, and based on a t-score (PROMIS, 2011).
For the variable anxiety, and depression, (negatively worded), a lower t-score is
better than average. For the variable ability to participate in social roles: (positively
worded) a lower t-score is worse than average. The average t-score is based on the U.S.
population and is normalized to 50.0 (PROMIS, 2011).
Data Handling
After I received IRB approval from Walden University on 28 September 2017
(approval number 09-28-17-0389089), I submitted a query for preexisting data from
USIDNET through IDF. This query netted PROMIS-29 patient data from 2015 through
May, 2017, and general patient registry data from April, 2008 through July, 2017. IDF
provided the query results in an email containing two Excel spreadsheets. The data were
downloaded onto a personal laptop, coded, and entered into SPSS. Data files were stored
on a personal password protected One Share cloud drive, and the original email was
stored in Outlook.
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Protection of Human Subjects
Data obtained for this study were obtained from USIDNET already de-identified.
Dissemination of Findings
Study findings will be presented to Walden University to support partial
fulfillment of academic requirement for a doctorate in public health. Although not
requested, findings might be disseminated to IDF and their patient, caregiver, and
advocate membership. The results of this study could be presented for publication in
peer-reviewed journals such as Journal of Clinical Immunology, BMC Public Health, or
Health Affairs.
Threats to Internal Validity
Threats to internal validity include the following biases which could have been
present in the populations I studied (namely, patients with PIDD who are listed in the IDF
patient registry and completed the PROMIS-29 survey, and who did not complete the
PROMIS-29 survey): (a) recall bias; (b) survey response bias (e.g. a tendency for a more
positive or more negative response to survey questions or questions about health; (c)
selection – history bias where patients using a given medical product might differ from
one another; and (d) selection – maturation where patients who previously took the
survey (which IDF solicits for completion twice annually) differ from those who have not
previously taken the PROMIS-29 survey, or patients who have used multiple types of
IGRT medical products versus those who have not (Blome & Augustine, 2015;
Frankfort-Nachmias & Nachmias, 2008). In the analysis phase, upon receiving IRB
approval, I looked to identify factors which compromise internal validity.
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Threats to External Validity (Generalizability)
The population of patients with PIDD could not be randomized. Thus, patients
consenting to take the PROMIS-29 instrument might not represent patients in IDF’s
registry who did not take the PROMIS-29 survey. Likewise, patients with PIDD in IDF’s
registry, of whom my population was a subset of this broader population, might not
represent the entire population of patients with PIDD globally. Ultimately, the goal was
to generalize across all patients with PIDD. Upon data analysis, I looked to identify
possible threats to external validity by comparing my dataset of individuals in IDF’s
patient registry who completed the PROMIS-29 survey with those in the same registry
who did not.
Summary
In this chapter, I presented the methods for understanding potential relationships
between patient preferences for treatment (desire for fewer needle sticks, and a shorter
infusion time) serving as the basis of manufacturers’ innovations in medical products
subsequently approved by the FDA and patients’ well-being (ability to participate in
social roles) and HRQOL (anxiety and depression) were presented. A query of all
USIDNET patient registry participants who gave consent to complete a PROMIS-29
survey netted a non-randomized population of 162 participants in the three available
study years 2015-2017. A query of the same patient registry from 2008 – 2017 netted a
non-randomized population of 1,939 participants available for comparison. In the
following chapter, statistical methods used to analyze data, and the results and meaning
of the data are presented. Additionally, I describe changes made to how the number of
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needle sticks was optimized upon examining the data, and how patients were categorized
into medical product innovation category.
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Chapter 4: Results
Introduction
The purpose of this dissertation was to compare the mean differences in HRQOL
and well-being as measured by PROMIS-29 for patients with PIDD who used medical
product manufacturers’ innovative medical products designed to have (a) fewer needle
sticks and (b) shorter infusion time to patients who did not use such products. I used a
secondary dataset from IDF to address the research questions. The six formulated
research questions had the following structure:
Needle Sticks: Is there a difference in X between patients with PIDD who report
using medical products innovated to offer therapeutic dosing with fewer needle sticks
every 3 or 4 weeks compared to those who report using medical products innovated to
offer therapeutic dosing with more needle sticks every 3 or 4 weeks?
Where X is (a) the well-being proxy PROMIS-29 score for “Ability to Participate
in Social Roles/ Activities,” (b) the HRQOL proxy PROMIS-29 score for “Anxiety,” or
(c) the HRQOL proxy PROMIS-29 score for “Depression.” Additionally, I defined fewer
needle sticks per 3 or 4 weeks as 1-8. This marks a change from my definition, given in
Chapters 1 and 3, of fewer needle sticks as 1 needle stick. This change in definition from
1 needle stick to fewer needle sticks accounts for patient choice to deliver less volume to
a single infusion site (single needle stick) by using up to four needles to infuse
simultaneously into four sites per infusion session, as allowed by the instructions on the
medical product. Thus, a patient infusing once per 14 days, and infusing into the

67
maximum of four sites (hence four needles) would encounter eight needle sticks in 3 or 4
weeks. I defined more needle sticks per 3 or 4 weeks as greater than 8 needles.
Infusion Time: Is there a difference in X between patients with PIDD who report
using medical products innovated for shorter infusion time compared to those who report
using medical products not innovated for shorter infusion time?
Where X is (a) the well-being proxy PROMIS-29 score for “Ability to Participate
in Social Roles/ Activities,” (b) the HRQOL proxy PROMIS-29 score for “Anxiety,” or
(c) the HRQOL proxy PROMIS-29 score for “Depression.” Additionally, shorter
infusion time was defined as 1-4 hours, and longer infusion time was defined as greater
than 4 hours.
The null and alternate hypotheses for each question, as well as the independent
and dependent variables were as follows:
H0: The mean differences were not statistically significant.
Ha: The mean differences were statistically significant.
Independent variables: needle sticks, infusion time.
Dependent variable: PROMIS score (Likert scale mean).
Data analysis occurred October 12-November 18, 2017 after receipt of Walden
IRB approval on September 28, 2017 (approval number 09-28-17-0389089) and upon
receipt of datasets from IDF on October 12, 2017. IDF had already granted approval on
October 20, 2016 (see Appendix A) and cosigned a revised Data Use Agreement with me
on October 13, 2017.
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In this chapter, I will address how I prepared the dataset for analysis. I will also
present my results. At the end of the chapter, I will include a summary of key points.
Data Collection
On September 28, 2017, I sent an e-mail to IDF requesting a refresh to the dataset
corresponding to my original query to USIDNET (see Appendix B) in order to have
PROMIS-29 data inclusive of the Spring 2017 issuance of the survey. Additionally, I
submitted a second query to USIDNET to obtain a dataset of individuals over the age of
18 years who had not completed a PROMIS-29 survey. This second query was
additional to the plan I outlined in Chapter 3. I submitted the second query for the
purpose of noting similarities and differences (see Tables 5 and 6) between individuals in
the patient registry who had completed a PROMIS-29 survey and those who had not.
Inclusion/Exclusion Criteria
The dataset of individuals who had completed a PROMIS-29 survey through
Spring 2017 included 162 subjects. Two of the 162 subjects received therapy via the
intramuscular route instead of by either the subcutaneous or the intravenous route of
administration. Although I included the two subjects in the data comparison with those
individuals who did not complete a PROMIS-29 survey, I excluded these individuals
from the data analysis supporting my research questions. Seven of the 162 subjects who
completed a PROMIS-29 survey reported they were not using any immunoglobulin
medical products. I considered that these seven individuals could be comparison controls
for the PROMIS-29 dependent variables; however, there were too few individuals for
inclusion to be a viable option. Although I excluded these seven individuals from the
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research question data analysis, I included them in the comparison with individuals who
did not complete a PROMIS-29 survey. The total number of subjects included in the
analysis of my research questions was 153, representing 162 subjects minus nine
excluded subjects.
The dataset of individuals who had not completed a PROMIS-29 survey included
1,939 subjects. The age range included 62 individuals who were 17 years old, and all
others were aged 18 and older. The individuals who took the PROMIS-29 survey were
aged 18 years and older. Therefore, the 62 individuals who were 17 years of age were
excluded, leaving a total of 1,877 subjects aged 18 years and older in the analysis.
Adding Context to the Medical Product Innovation Categorical Values
I originally planned to use medical product labeling to determine fewer versus
more needle sticks. As such, I determined that one needle stick every 3 or 4 weeks could
suffice as the operationalization of the concept term “fewer.” However, as I analyzed the
dataset, I noted that some patients indicated the interval of days in which they infused a
medical product. Therefore, a patient infusing a product at the allowed rate of once every
14 days, and using up to four injection sites allowed on the medical product labeling,
would infuse using eight needles per month. A patient who infused the same medication
daily as allowed by the medical product labeling would use 30 or more needles per
month. The dataset revealed that patients who reported an infusion interval reported
intervals of 1, 3, 4, 7, 14, 21, 25, 28, 30, or 42 days. Thus, when an individual provided
interval of infusion, I categorized him or her according to this information along with
medical product labeling information. In order to align the specific statement of one
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needle stick in my research question with my dataset, I had to increase the number of
needlesticks representing “fewer” to eight needle sticks. Thus, I defined more needle
sticks as more than eight.
Demographics
As mentioned in Chapter 3, for the purpose of my dissertation research, my
dataset consisted of the entire population of individuals who had taken the PROMIS-29
survey. However, this population of PROMIS-29 survey takers is a subset of all patients
in IDF’s patient registry. In order to support generalizability to the entire registry, I
assessed available data which were common to all individuals in the patient registry in
order to compare those who took the PROMIS-29 survey and those who did not. Table 5
shows demographics of individuals in the patient registry segmented into whether or not
they had taken the PROMIS-29 survey.
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Table 5
Comparison Demographics of Individuals Who Took the PROMIS-29 Survey and Those
Who Did Not Take the PROMIS-29 Survey

Gender
Male
Female
Race
Asian
Black
Native American
White
Hispanic Latin
Other/ Mixed
Administration
IM
IV
SC
None
Disability
None
Partial
Full

PROMIS-29
N (%)
162 (100%)
33 (20.4)
129 (79.6)
162 (100%)
1 (0.6%)
0 (0)
0 (0)
161 (99.4%)
0 (0)
0 (0)
162 (100%)
2 (1.2%)
76 (46.9%)
77 (47.5%)
7 (4.3%)
31 (100%)
20 (64.5%)
7 (22.6%)
4 (12.9%)

Non PROMIS-29
N (%)
1877 (100%)
814 (43.4%)
1063 (56.6%)
1397 (100%)
22 (1.6%)
67 (4.8%)
6 (0.4%)
1195 (85.5%)
53 (3.8%)
54 (3.9%)
1415 (100%)
3 (0.2%)
744 (52.6%)
308 (21.8%)
360 (25.4%)
697 (100%)
400 (57.4%)
250 (35.9%)
47 (6.7%)

Gender and Race. The majority of the individuals in both groups were White
females. However, the population of individuals who took the PROMIS-29 survey was
less balanced in terms of gender (79.6% female/ 20.4% male) compared with those in the
registry who had not taken the PROMIS-29 survey (56.6% female/ 43.4% male). The
same applied to race, where nearly all of the individuals who took the PROMIS-29
survey were White (99.4%), compared with those who did not take the PROMIS-29
survey (85.5%). I conducted a chi-square test of independence to determine whether
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gender and race were equally distributed among the PROMIS-29 and non-PROMIS-29
individuals in the patient registry.
A chi-square test of independence was conducted between gender and PROMIS29 survey status. All expected cell counts were greater than five. There was a
statistically significant association, and the null hypothesis that there was no association
between gender and whether or not individuals had taken the PROMIS-29 survey was
rejected. Thus, χ2(1) = 32.476, p < .005. The association was small, Cramer’s V =.126
(Cohen, 1988). Gender was not equally distributed between the two populations.
A chi-square test of independence was conducted between race and PROMIS-29
survey status. Two cells (16.7%), Asian and Native American for those who had taken
the PROMIS-29 survey, had expected counts less than five. According to Yates, Moore,
and McCabe (1999) if the number of cells with expected counts less than five is not more
than 20% and if no single cell has an expected count less than one, the chi-square statistic
might still be considered valid. There was a statistically significant association, and the
null hypothesis that there was no association between race and whether or not individuals
had taken the PROMIS-29 survey was rejected. Thus, χ2(5) = 24.973, p < .005. The
association was small, Cramer’s V =.127 (Cohen, 1988). I determined to perform the
chi-square test again after collapsing the number of race categories by combining Asian,
Black, and Native American into a single category. This time, all expected cell counts
were greater than five. Both sets of chi-square results were similar. Again, there was a
statistically significant association between race and PROMIS-29 survey status, χ2(3) =
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24.618, p <.005. The association was small, Cramer’s V = .126. Race was not equally
distributed between the two populations.
Route. Of the individuals reporting whether they received their IGRT regimen by
IM, IV, SC, or None (i.e. they were not receiving IGRT medication), the population of
PROMIS-29 survey takers were split roughly 50:50 between the IV and SC routes.
Whereas, those who had not taken the PROMIS-29 survey were split between the
majority using IV, followed by those who were not receiving IGRT, and lastly by the SC
route. Notably, while all individuals who had taken the PROMIS-29 survey reported, the
524 missing values for those who had not taken the PROMIS-29 survey might have
skewed the results.
A chi-square test of independence was conducted between PROMIS-29 survey
status and route of administration. Two cells (25.0%), the IM route of therapy
administration, had expected counts less than five. According to Yates, Moore, and
McCabe (1999) if the number of cells with expected counts less than five is not more
than 20% and if no single cell has an expected count less than one, the chi-square statistic
might still be considered valid. Because my results did not meet this requirement, I used
the two-tailed Fisher’s Exact test to determine whether there was a statistically significant
difference between those who had taken the PROMIS-29 survey and those who had not
taken the PROMIS-29 survey as regards route of therapy administration. The results
indicated that there was a statistically significant difference between the PROMIS-29
survey takers and the other individuals in the patient registry as regards route of therapy.
The null hypothesis is that there was no difference. The results indicated there was a
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significant association and the null hypothesis was rejected (p = <.001, df = 3, Fisher’s
Exact Test = 76.464).
Disability. More than half of individuals in both groups reported having no
disability (e.g. normal activity, and a range of none to some evidence of disease);
followed by partial disability (e.g. ranging from ability to care for self but inability to
carry out normal activities to requiring extensive care, and frequent medical care); and
the fewest reported full disability (e.g. very ill, specialized care, and hospitalization).
Though the percentages of the range of disability varied across those who took the
PROMIS-29 survey versus those who did not, the results of a two-tailed Fisher’s Exact
Test failed to reject the null hypothesis that there is no difference between two sets of
individuals in terms of disability (p = .166, df = 2, Fisher’s Exact Test = 3.562).
Individuals who completed a PROMIS-29 survey were also compared to those
who did not in terms of chronological age and age at PIDD symptom onset, age at
diagnosis, age at initiation of IGRT, and IGRT infusion interval. These comparisons are
presented in Table 6.
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Table 6
Comparison Characteristics of Individuals Who Took the PROMIS-29 Survey and Those
Who Did Not Take the PROMIS-29 Survey
PROMIS-29

Non PROMIS-29

Age (years)
N
Mean
Median
Mode
Min
Max

162
53
56
58
18
82

1877
39
35
19
18
95

Age at PIDD symptom onset (years)
N
Mean
Median
Mode
Min
Max

43
25
24
0
0
58

1008
16
10
0
0
77

Age at PIDD diagnosis
N
Mean
Median
Mode
Min
Max

100
43
46
51
1
78

1261
25
19
2
0
82

IG Starting Age (years)
N
Mean
Median
Mode
Min
Max

71
45
48
32
15
69

678
29
26
14
0
81

IG Infusion Interval (days)
N
Mean
Median
Mode
Min
Max

133
17
14
7
1
42

985
21
28
28
1
90
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Results shown in Table 6 reveal the mean age of individuals who completed the
PROMIS-29 survey was 14 years older than those in the patient registry who did not. A
Mann-Whitney U test was run to determine if there were differences in age between those
who took the PROMIS-29 survey and those who did not. Distributions of age values
were considered by visual inspection and were not similar. Age values for those who
took the PROMIS-29 survey (mean rank = 196.03) were statistically significantly higher
than for those who did not take the PROMIS-29 survey (mean rank = 132.66), U =
5,416.000, z = 4.080, p = <.001. Additionally, those who took the PROMIS-29 survey
were on average nine years older when symptoms appeared. A Mann-Whitney U test
was run to determine if there were differences in PIDD symptom onset between those
who took the PROMIS-29 survey and those who did not. Distributions of PIDD
symptom onset age values were considered by visual inspection and were not similar.
PIDD symptom onset age values for those who took the PROMIS-29 survey (mean rank
= 179.17) were statistically significantly higher than for those who did not take the
PROMIS-29 survey (mean rank = 134.70), U = 4,910.000, z = 2.862, p = .004.
As a result of older age at symptom onset, on average, those who took the PROMIS-29
survey also were 18 years older when diagnosed and 16 years older when they started
IGRT. A Mann-Whitney U test was run to determine if there were differences in age at
PIDD diagnosis between those who took the PROMIS-29 survey and those who did not.
Distributions of age at PIDD diagnosis were considered by visual inspection and were not
similar. Age at PIDD diagnosis values for those who took the PROMIS-29 survey (mean
rank = 206.20) were statistically significantly higher than for those who did not take the
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PROMIS-29 survey (mean rank = 131.43), U = 5,721.000, z = 4.811, p < .001. Likewise,
a Mann-Whitney U test was run to determine if there were differences in age at the start
of IGRT between those who took the PROMIS-29 survey and those who did not.
Distributions of age at the start of IGRT were considered by visual inspection and were
not similar. Age at the start of IGRT for those who took the PROMIS-29 survey (mean
rank = 196.13) was statistically significantly higher than for those who did not take the
PROMIS-29 survey (mean rank = 132.65), U = 5,419.000, z = 4.085, p < .001.
The mean delay in diagnosis (I defined this as the difference between the mean
age at symptom onset and the mean age at diagnosis) was twice as long for those who
took the PROMIS-29 survey (18 years) compared with those who did not take the
PROMIS-29 survey (nine years). Lastly, the mode for infusion interval was 7 days for
those who took the PROMIS-29 survey (suggesting a greater proportion of individuals
who use the SCIG route of administration), versus 28 days for those who did not take
PROMIS-29 (suggesting a greater proportion of individuals who use the IVIG route of
administration). Aligned with Table 5, comparing across the two groups, these data
support that a greater proportion of individuals who took the PROMIS-29 survey were
using the SCIG route of administration (i.e. generally more frequent administration
ranging from daily, to every few days, weekly, or every 14 days) and a greater proportion
of individuals who did not take the PROMIS-29 survey were using the IVIG route of
administration (i.e. generally monthly administration). A Mann-Whitney U test was run
to determine if there were differences in interval of days of IGRT infusion between those
who took the PROMIS-29 survey and those who did not. Distributions of IGRT infusion
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days interval were considered by visual inspection and were not similar. The IGRT
infusion days interval for those who took the PROMIS-29 survey (mean rank = 96.97)
was statistically significantly shorter than for those who did not take the PROMIS-29
survey (mean rank = 144.65), U = 2,444.000, z = -3.169, p = .002.
Analysis of Research Questions
In Chapter 3 I outlined a plan for using two-tailed independent t-tests to address
my research questions. Additionally, I planned to use ANCOVA to analyze age, and
median annual income as covariates. During the course of analysis, I found my data did
not always meet some of the requirements regarding outliers, normality, and
homogeneity of variances, even when I did a log10 or a square root transformation.
Therefore, for each question I describe when assumptions were not met and the
alternative methods applied.
Additionally, as I mentioned in Chapter 3, PROMIS-29 scores are written as a tscore where the average, based on the U.S. population, is 50.0. Each individual score
was presented as an average t-score with a ± standard error. In order to simplify the
analyses, I used the PROMIS-29 scoring manual to convert the t-scores back to the Likert
raw scores (PROMIS, 2015).
Hypothesis 1 – Needle Sticks and Well-being (Ability). The null hypothesis for
research question 1 was that there would be no difference in mean PROMIS-29 “Ability
to Participate in Social Roles/ Activities” scores for patients with PIDD who used
medical products innovated for fewer needle sticks versus those who used medical
products which were not innovated for fewer needle sticks.
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A total of 92 individuals were categorized as having fewer needle sticks, and 51
individuals were categorized as having more needle sticks. I ran a two-tailed independent
t-test to determine if there were mean differences in ability to participate in social roles/
activities in those taking the innovative medical products compared to those who were
not. There were outliers (see Figure 2) in the data, as assessed by inspection of a boxplot.
Therefore, a Mann-Whitney U test was also conducted.

Figure 2. Boxplot of well-being (ability to participate in social roles/activities) and
needle sticks.
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PROMIS-29 scores were normally distributed as determined by skewness and
kurtosis (.009 and -.498, respectively for fewer needle sticks; and -.320 and .285,
respectively for more needle sticks) values between ±1, and by inspection of a histogram
and Q-Q plot. There was homogeneity of variances as assessed by Levene’s test for
equality of variances (p = .197).
A two-tailed independent t-test revealed individuals using medical products
innovated for fewer needle sticks (M = 11.79, SD = 3.946) did not have statistically
significant different levels of well-being/ ability to participate in social roles/ activities
compared to individuals using medical products which were not innovated for fewer
needle sticks (M = 12.08, SD = 3.725), M = -.285, 95% CI [-1.620, 1.050], t (141) = .422, p = .674.
Additionally, a Mann-Whitney U test revealed median PROMIS-29 scores for
“Ability to Participate in Social Roles/ Activities” did not differ significantly for patients
with PIDD who used medical products innovated for fewer needle sticks (Median =
12.00) compared to those who did not (Median = 12.00), U = 2782.000, z = 0.252, p =
.801.
Hypothesis 2 – Needle Sticks and HRQOL (Anxiety). The null hypothesis for
research question 2 was that there would be no difference in mean PROMIS-29
“Anxiety” scores for patients with PIDD who used medical products innovated for fewer
needle sticks compared to those who used medical products which were not innovated for
fewer needle sticks.
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A total of 92 individuals were categorized as having fewer needle sticks, and 51
individuals were categorized as having more needle sticks. An independent t-test was run
to determine if there were mean differences in anxiety in those taking the innovative
medical products compared to those who were not. There were no outliers in the data, as
assessed by inspection of a boxplot.
PROMIS-29 scores were fairly normally distributed as assessed by skewness and
kurtosis values (-.070 and -1.160, respectively for fewer needle sticks, and .396 and .412, respectively for more needle sticks) between ±1, and inspection of a histogram and
a Q-Q plot. There was homogeneity of variance as assessed by Levene’s test for equality
of variances (p = .095). Individuals using medical products innovated for fewer needle
sticks (M = 9.50, SD = 3.421) did not have statistically significant different levels of
anxiety, HRQOL/ anxiety than individuals using medical products not innovated for
fewer needle sticks (M = 8.73, SD = 3.020), M = .775, 95% CI [-.359, 1.908], t (141) =
1.351, p = .179.
Additionally, according to the Mann-Whitney U test, median PROMIS-29 scores
for Anxiety did not differ significantly for patients with PIDD who used medical products
innovated for fewer needle sticks (Median = 10.00) compared to those who did not
(Median = 8.00), U = 2420.500, z = -1.125, p = .260.
Hypothesis 3 – Needle Sticks and HRQOL (Depression). The null hypothesis
for research question 3 was that there would be no difference in mean PROMIS-29
“Depression” scores for patients with PIDD who used medical products innovated for
fewer needle sticks versus those who used medical products which were not innovated
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for fewer needle sticks.
A total of 92 individuals were categorized as having fewer needle sticks, and 51
individuals were categorized as having more needle sticks. I ran an independent t-test to
determine if there were mean differences in depression in those taking innovative medical
products compared to those who were not. There were no outliers in the data, as assessed
by inspection of a boxplot. PROMIS-29 scores were fairly normally distributed as
determined by skewness and kurtosis values (.456 and -.523, respectively for fewer
needle sticks, and .365 and -1.019, respectively for more needle sticks) between ±1, and
inspection of histograms and Q-Q plots. There was homogeneity of variances as assessed
by Levene’s test for equality of variances (p = .084). Individuals using medical products
innovated for fewer needle sticks (M = 8.86, SD = 3.839) did not have statistically
significant different levels of HRQOL/ depression than individuals using medical
products not innovated for fewer needle sticks (M = 8.00, SD = 3.225), M = .859, 95% CI
[-.395, 2.113], t (141) = 1.354, p = .178.
Additionally, a Mann-Whitney U test revealed median PROMIS-29 scores for
Depression did not differ for patients with PIDD who used medical products innovated
for fewer needle sticks (Median = 9.00) compared to those who did not (Median = 8.00),
U = 2,471.000, z = -.933, p = .351.
Hypothesis 4 – Infusion Time and Well-being (Ability). The null hypothesis for
research question 4 was that there would be no difference in mean PROMIS-29 “Ability
to Participate in Social Roles/ Activities” scores for patients with PIDD who used
medical products innovated for shorter infusion time versus those who used medical
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products which were not innovated for shorter infusion time. A total of 71 individuals
were categorized into having shorter infusion times, and 72 individuals were categorized
into having longer infusion times. A Welch t-test was run to determine if there were
differences in ability to participate in social roles between shorter infusion times and
longer infusion times due to the assumption of homogeneity of variance being violated,
as assessed by Levene’s test for equality of variances (p = .027). Additionally, visual
inspection of a boxplot of the data revealed outliers. Data were normally distributed
based on skewness and kurtosis values (-.541 and .514, respectively for shorter infusion
time, and .251 and -.547, respectively for longer infusion time) between ±1, and
inspection of histograms and Q-Q plots. There was no difference in the mean PROMIS29 scores for individuals using medical products innovated for shorter infusion times (M
= 12.34, SD = 3.497) and those innovated for longer infusion times (M = 11.46, SD =
4.162). Well-being for both groups was not statistically significantly different M = .880,
95% CI [-.391, 2.150], t (137.542) = 1.369, p = .173.
The test for homogeneity of variance did not meet the assumption required for
performing an independent t-test. Therefore, a Mann-Whitney U test was also conducted.
Median PROMIS-29 scores for Ability to participate in social roles/ activities did not
differ significantly for patients with PIDD who used medical products innovated for
shorter infusion times (Median = 12.00) compared to those who did not (Median =
12.00), U = 2,486.000, z = -1.619, p = .105.
Hypothesis 5 – Infusion Time and HRQOL (Anxiety). The null hypothesis for
research question 5 was that there would be no difference in mean PROMIS-29
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“Anxiety” scores for patients with PIDD who used medical products innovated for
shorter infusion time versus those who used medical products which were not innovated
for shorter infusion time.
A total of 71 individuals were categorized into having shorter infusion times, and
72 individuals were categorized into having longer infusion times. A Welch t-test was
run to determine if there were differences in anxiety between shorter infusion times and
longer infusion times due to the assumption of homogeneity of variances being violated,
as assessed by Levene’s test for quality of variances (p = .005). There were no outliers.
Data were fairly normally distributed based on skewness and kurtosis values (.227 and .637, respectively for shorter infusion times, and -.062 and -1.272, respectively for longer
infusion times). There was no difference in the mean PROMIS-29 scores for individuals
using medical products innovated for shorter infusion times (M = 8.93, SD = 2.885) and
those innovated for longer infusion times (M = 9.51, SD = 3.650), HRQOL/ Anxiety for
both groups was not statistically significantly different M = -.584, 95% CI [-1.672, .503],
t (134.644) = -1.063, p = .290.
The non-parametric Mann-Whitney U test revealed similarly. Median PROMIS29 scores for Anxiety did not differ significantly for patients with PIDD who used
medical products innovated for shorter infusion time (Median = 9.00) compared to those
who did not (Median = 10.00), U = 3,175.000, z = -.914, p = .361.
Hypothesis 6 – Infusion Time and HRQOL (Depression). The null hypothesis
for research question 6 was that there would be no difference in mean PROMIS-29
“Depression” scores for patients with PIDD who used medical products innovated for
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shorter infusion time versus those who used medical products which were not innovated
for shorter infusion time.
A total of 71 individuals were categorized into having shorter infusion times, and
72 individuals were categorized into having longer infusion times. A Welch t-test was
run to determine if there were differences in HRQOL /depression between shorter
infusion times and longer infusion times due to the assumption of homogeneity of
variances being violated, as assessed by Levene’s test for quality of variances (p = .001).
There were no outliers, and the data were relatively normally distributed as determined
by assessing skewness and kurtosis values (.236 and -1.009, respectively and .430 and .775, respectively) between ±1, and histograms and Q-Q plots. There was no difference
in the mean PROMIS-29 scores for individuals using medical products innovated for
shorter infusion times (M = 8.14, SD = 3.030) and those innovated for longer infusion
times (M = 8.96, SD = 4.143), HRQOL/ Depression for both groups was not statistically
significantly different M = -.817, 95% CI [-2.017, .382], t (130.082) = -1.348, p = .180.
According to the non-parametric Mann-Whitney U test, depression did not differ
for patients with PIDD who used medical products innovated for shorter infusion time
(Median = 8.00) than for those who did not (Median =8.00), U = 3,119.000, z = .708, p =
.479.
Covariates Assessment. I conducted an Analysis of Covariance (ANCOVA) to
evaluate adjustments to the mean differences of the PROMIS-29 measures across each
level of medical product innovation by treating age and median annual income as
covariates. Inspection of a scatter plot revealed a linear relationship between the

86
PROMIS-29 measures and medical product innovation category for needle sticks and for
infusion time. There was homogeneity of regression slopes as evidenced by nonstatistically significant results. A Shapiro-Wilks test showed that some levels of the
independent variable (e. g. fewer/ more needle sticks, and shorter/ longer infusion time)
were non-significant while some were significant. There was homoscedasticity as
evidenced through visual inspection of a scatterplot. The assumption of homogeneity of
variance, as measured by Levene’s test was not met. There were no instances of
standardized residuals greater than ±3 standard deviations. After adjusting for age and
for median annual household income, there still was no statistical difference in the mean
PROMIS-29 scores for individuals using medical products innovated for fewer needle
sticks or shorter infusion time, and those who were not.
PROMIS-29 Scores and Switching Therapy. The dataset of individuals who
had completed the PROMIS-29 survey included those who had reported, including dates,
one or more changes of medical products. I ran a two-way independent t-test to
determine whether there was a significant difference in mean PROMIS-29 scores for
individuals who reported changing medical products (n = 24) and those who had not (n =
129). Inspection of boxplots showed the data had no outliers. Data were fairly normally
distributed as evidenced by inspection of Q-Q plots and observation that skewness and
kurtosis values were between ±1 for each level of independent variable (with the
exception of the anxiety PROMIS-29 measure for those who changed medical products:
skewness = -.074, kurtosis = -1.305). Since those who changed medical products
numbered less than 50 individuals, I also examined the Shapiro-Wilk test of normality
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results. The Shapiro-Wilk results were not significant (p = .314 for ability to participate;
p = .100 for anxiety; and p = .263 for depression). Levene’s tests for homogeneity of
variance revealed the assumption of homogeneity was met for the PROMIS-29 HRQOL
measures, anxiety (p = .875) and depression (p = .327).
The difference in mean PROMIS-29 HRQOL anxiety scores for individuals who
changed medical product (M = 9.92, SD = 3.269) and those who did not change medical
product (M = 9.19, SD = 3.319) was not statistically significant, M = -.723, 95% CI [2.177, .732], t (151) = -.982, p = .328.
The difference in mean PROMIS-29 HRQOL depression scores for individuals
who changed medical product (M = 9.13, SD = 3.379) and those who did not change
medical product (M = 8.53, SD = 3.657) was not statistically significant, M = .989, 95%
CI [-2.178, .998], t (151) = -.734, p = .464.
For the PROMIS-29 well-being variable, ability to participate in social roles/
activities, the assumption of homogeneity of variances was violated as evidenced by
Levene’s test for equality of variances (p = .037). Therefore, a Welch t-test was run. The
difference in mean PROMIS-29 well-being scores for individuals who changed medical
product (M =11.04, SD = 4.486) and those who did not change medical product (M =
12.03, SD = 3.618) was not statistically significant, M = .989, 95% CI [-.994, 2.973], t
(28.828) = 1.020, p = .316.
Individuals who switched products and took multiple PROMIS-29 surveys
The PROMIS-29 survey is offered approximately every six months, and three
individuals who completed a survey at more than one-time point and also reported

88
changing medical products from one which had been on the market prior to 2010 to a
medical product which has been approved between 2010 and present. Table 7 provides a
summary of the data. The maximum raw score in each domain (i.e. ability, anxiety, and
depression) is 20, and the minimum is four. For each domain, a higher score means the
individual reported feeling more of that domain. Results show that each individual
reported increased well-being, as measured by the PROMIS-29 ability to participate in
social roles/ activities from their first to their second survey time point. Levels of
HRQOL related to the PROMIS-29 domain for anxiety remained unchanged for Person
ID 931 and Person ID 2685; and anxiety decreased for Person ID 8121 from their first to
their second survey time point. Levels of HRQOL related to the domain for depression
revealed Person ID 931 unchanged. However, Person ID 2685 and Person ID 8121
reported a decrease in depression from their first to their second time taking the
PROMIS-29 survey. Overall gains in HRQOL and well-being totaled +1 point for
Person ID 931, +6 points for Person ID 2685, and +15 points for Person ID 8121.
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Table 7
Scores for Individuals Who Changed Medical Products and Took the PROMIS-29 Survey
at Two Different Time Points
Person ID
PROMIS-29 measure
931
Ability
Anxiety
Depression
2685
Ability
Anxiety
Depression
8121
Ability
Anxiety
Depression

PROMIS-29
score - Time 1

PROMIS-29
score - Time 2

19
5
5

20
5
5

9
10
11

11
10
7

5
16
17

8
13
8

Summary
In conclusion, individuals using medical products innovated for fewer needle
sticks or for shorter infusion time had similar mean HRQOL and well-being as measured
by the PROMIS-29 survey. The same held true when PROMIS-29 data were evaluated
according to individuals who had reported switching medical products compared to those
who had not. Thus, the null hypothesis of no mean difference between the two groups
could not be rejected. Overall, individuals were equally able to participate in social
activities/ roles. Overall, individuals were equally likely to be more or less anxious or
depressed. Thus, individuals had the same HRQOL and well-being for the medical
product they were using at the time they took the PROMIS-29 survey. However, when
looking at the same individuals when they changed medical products to a newly
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innovated product (e.g. approved 2010 to present) and also took the PROMIS-29 survey
at approximately the time point of the change, the limited data suggest improvements in
well-being and HRQOL.
An assessment of parameters common to all individuals in the patient registry
demonstrated that those who took the PROMIS-29 survey and those who did not were
similar in disability distribution. However, the groups differed in other key aspects such
as gender, racial, and age distribution. Furthermore, the groups differed in disease state
parameters such as age at: symptom onset, diagnosis, and initial use of IGRT. As a result
of these differences, it is difficult to generalize the research question findings to the entire
population of individuals in the patient registry.
In Chapter 5, I will consider the implications of the findings in context of the
literature review from Chapter 2 and in terms of potential research areas of the future
research.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
In this quantitative dissertation, I evaluated the impact on well-being and HRQOL
of medical products for PIDD innovated according to patient preferences for fewer needle
sticks and shorter infusion times by analyzing PROMIS-29 survey scores. I used the
PROMIS-29 domain “Ability to Participate in Social Roles/Activities” as a proxy for
well-being, and the domains of “Anxiety” and “Depression” as proxies for HRQOL. As I
noted in Chapter 1, well-being conceptualizes how people thrive in their daily life while
HRQOL is associated with negative emotions (HealthyPeople.gov, 2017).
I used t-tests and Mann-Whitney tests to measure whether there were differences
in the PROMIS-29 scores according to medical product innovation category. In each
case, I failed to reject the null hypothesis that there is no mean difference. In order to
determine generalizability between the 153 individuals who completed the survey and the
1,877 individuals in the patient registry who did not take the PROMIS-29 survey, I
compared common characteristics such as age, gender, race, route of IGRT
administration, level of disability, age at PIDD symptom onset, age at diagnosis, and age
at first IRGT use. Statistical analyses revealed significant differences between the
populations for all aspects compared, except for level of disability. Thus, I cannot
generalize from individuals in the patient registry who took the PROMIS-29 survey to
those individuals in the patient registry who did not.
Next, I compared the mean difference in PROMIS-29 scores between individuals
who reported using a medical product approved in the time frame of 2010-2014 and those

92
who reported using a medical product approved prior to 2010. There was no statistically
significant difference in PROMIS-29 scores, and I failed to reject the null hypothesis.
Each group had similar levels of HRQOL and well-being.
Lastly, three individuals in my dataset reported having changed from a medical
product innovated prior to 2010 to a medical product innovated in 2010 or later and also
took the PROMIS-29 survey around the periods of time when they switched. My data
suggest that there might be improvements in HRQOL and well-being as measured by
PROMIS-29 due to the switch to innovative medical product for these individuals.
Interpretation of the Findings
The underlying premise of the research questions is that patients have a treatment
preference for shorter infusion time and fewer needle sticks (Jiang et al., 2015); thus,
patients taking those medical products would have a higher mean HRQOL and a higher
mean well-being than patients who did not take these products. However, the null
hypothesis that there would be no mean difference could not be rejected. There might be
several reasons for this finding, including: (a) perhaps patients were already optimized on
a therapy regimen of their preference at the time they took the PROMIS-29 survey; (b)
statistical power to detect a difference was not present; (c) other factors distributed
among the groups were more influential; (d) preference for treatment, satisfaction with
treatment, and HRQOL/well-being, while seemingly similar constructs, might be
different enough that their measurement involves generating primary data asking specific
linking questions between innovated medical products and the PROMIS-29 survey
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questions; and (e) improvements in HRQOL and well-being are best measured using a
longitudinal design rather than a cross-sectional design.
The study findings presented in Chapter 4 are similar to those of other studies.
For instance, while some researchers have found statistically significant differences or
changes in HRQOL and well-being, other researchers have found no significant
differences or changes. Bienvenu et al (2016) and Espanol et al (2014) both found no
statistical difference between the route of administration (IV and SC) and quality of life
as measured by SF-36 and SF-12, respectively. Other researchers found no difference in
QOL as measured by SF-12 between treatment bother (e.g., treatment convenience,
interruptions to life, side effects and reactions, needle sticks, infusion time, number of
infusions, infusion costs, and operation of infusion delivery medical devices) and route of
administration (Rider et al., 2017).
In general, route of administration influences the number of needle sticks and the
infusion time. Individuals receiving therapy via subcutaneous injections generally
receive smaller doses daily to weekly, or biweekly. Therefore, there is potential for more
needle sticks but shorter infusion times. Individuals receiving intravenous injections
generally receive a large monthly dose and have the potential for fewer injections but
longer infusion times. Medical product innovations include making available more
concentrated formulations (e.g., 5%, 10%, 16%, and 20% formulations exist) so the same
concentration of therapy can potentially be administered in reduced time and with fewer
needle sticks. Other innovations include medical products which allow administration of
more volume per infusion, thus potentially reducing the number of needle sticks and
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infusion time (Kobrynski, 2012). However, the proportion of individuals who took the
PROMIS-29 survey using newer innovative medical products might have been too few to
detect a difference. For example, 63 patients were using medical products approved
since 2010, and only 15 patients were using medical products approved since 2012.
The findings of this study are supported by literature. However, mean differences
in HRQOL and well-being might also have been nonexistent due to patients having
already been optimized according to the medical products available to them. For
instance, data suggested potential improved HRQOL and well-being when the same
individual took the PROMIS-29 survey around the same time point of changing medical
products (see Table 7). Lastly, mean differences might also have been masked by lack of
statistical power and the small numbers of individuals using the newer innovated medical
products.
Some researchers have found that clinical condition (e.g., number and severity of
infections and comorbidities such as impaired digestive, liver, lung, or neurological
functioning) is a greater influence on HRQOL than therapy parameters (Rider et al.,
2017; Tabolli et al, 2014). Rider et al. (2017) found that higher QOL was associated with
patients having controlled PIDD and limited physical impairment. Additionally, patients
who also were not bothered by requirements of treatment (including needle sticks and
infusion times), and who received infusions at home (whether IGIV or SCIG), had higher
QOL (Rider et al., 2017). Rider et al. (2017) found that patients who reported having no
physical impairment scored higher than the U.S. population for QOL. The authors found
this aspect surprising because patients with PIDD generally score lower than the U.S.
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population on QOL measures (Rider et al., 2017). However, these findings align with the
disability paradox theoretical framework (see Albrecht & Devlieger, 1999; Fellinghauer
et al., 2012) discussed in Chapters 1 and 2.
My study findings might be indicative that the ultimate goal of aligning patients
with medical products catering to their preferences, and thus optimizing their HRQOL
and well-being has been achieved for this population of individuals with PIDD. For
instance, researchers found that patients were satisfied with the therapy they were
receiving (Bienvenu, 2016). According to Espanol et al., (2014), satisfaction with
treatment was related to preferences. Individuals who preferred one needle stick once a
month were satisfied if they were receiving IVIG. Additionally, individuals who were
satisfied with SCIG preferred self-infusion at home (Espanol et al., 2014). The
availability, since 2010, of medical products allowing more choice about when and where
patients can potentially receive fewer needle sticks and which have a shorter infusion
time (Ponsford, 2015; Wasserman, 2014) could shift preferences or reasons for patient
satisfaction as more patients begin using these medications. In Chapter 1, I mentioned
the medical product supply chain leading to medical product availability for physicians to
prescribe. Espanol et al. (2014) and Seeborg et al. (2015) commented that therapy and
route of administration are influenced to a large extent by the physician. These
researchers urged the need to ensure patient preference considerations in order to
facilitate better HRQOL and perceived health outcomes. The balancing act of
maintaining stable blood serum levels of antibody at the clinical level to stave off chronic
infections while measuring treatment preference and treatment satisfaction has been a
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need demonstrated in the literature. In this study, I used the biopsychosocial model
theoretical framework to study psychosocial factors assessed via the PROMIS-29 survey
on IGRT standard and innovative medical products already proven and approved
according to clinical outcomes (e.g. stable blood serum levels, fewer infections and
hospitalizations, leading to fewer missed days of work/ school).
Limitations of Study
I used a secondary dataset where the data collected was not specific to my
research questions. Regarding needle sticks, some individuals provided information
about the interval of days between infusions. This enabled patient-specific placement
into a category based on their actual use. For patients who did not report IGRT interval, I
inferred needle stick information from medical product labeling. Regarding infusion
time, there was no available data about infusion time specific to each patient. Therefore,
I also inferred this information from medical product labeling. However, there might
have been a significant level of variability within my study population within the
parameters of medical product labeling. Other limitations included potential confounding
factors for which data were not available; for example, the length of time patients had
been receiving their current medical product and/ or therapy, and how successful they
feel therapy has been. Limitations associated with PROMIS-29 survey administration
include those named in Chapter 1 and Chapter 3 regarding selection bias, recall bias, and
survey response bias.
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Recommendations
Patient-reported outcomes such as preferences for treatment, satisfaction with
treatment, and aspects of treatment which lead to increased HRQOL and well-being are
not necessarily intuitive. For instance, Elliott & Richardson (2014) noted persons with
epilepsy preferred not solely a reduction in the number and severity of seizures, they also
preferred alleviation of the depressive and anxiety manifestations of epilepsy which
prevented performing functions of life, such as work and school. Instead of a cure from
the disease state for patients with rare and common chronic diseases, there is daily
management and a series of tradeoffs (e.g. medication already in liquid form instead of as
a lyophilized powder needing to be reconstituted with sterile water; medication which can
remain at room temperature versus needing refrigeration; medication which can be taken
less often, or on an empty stomach; or more than one option for route of administration).
Thus, patient-reported outcomes are a powerful tool for understanding how to make
outcomes better for patients. The biopsychosocial model demands a biomedical
demonstration of medical product performance, and the model demands this clinical
performance also considers the psychosocial world of the patient. Gathering primary data
for further study of patient-reported outcomes using the biopsychosocial model
framework would further the evidence base and scientific discourse for innovative
medical product development and for regulatory decision-making.
Implications for Positive Social Change
This is the first study which used the biopsychosocial model framework to test
whether patient preferences realized into medical products and therapy regimens
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translated to increased HRQOL and well-being when measured by the PROMIS-29
survey for patients with PIDD. Research aimed at studying patient psychosocial
perspectives additional to biomedical perspectives has a potential impact at the individual
level and at the societal/ policy level because it provides an evidence base for medical
product development and approval. Implications for positive social change include
helping medical product manufacturers and regulatory bodies to verify innovative
medical products have impact on patient lives beyond solely biomedical parameters and
clinical endpoints and then to make these products available to patients. This dissertation
serves as a guide for how a theoretical framework such as the biopsychosocial model can
be used along with the PROMIS-29 survey to gain patient feedback and to assess
innovations made in response to patient feedback for PIDD and other chronic disease
states.
I recommend this study be conducted using a longitudinal design where
individuals about to experience an innovative medical product get a pretest and a posttest
asking specific questions about their preferences and the medical product innovation, and
they are provided the PROMIS survey instrument. Thus, the voice of the patient will
have an opportunity to be heard with less confounding and with more statistical power to
form a stronger evidence base.
Conclusions
The findings of this study showed that patients with PIDD are generally equal in
terms of HRQOL and well-being across the variety of IGRT medical products. Some of
the prior studies reviewed support this finding. However, gaining the voice of the patient
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is valuable to society. Thus, this study merits repeating using a longitudinal design and
questions specifically aimed toward linking patient preferences for treatment with the
PROMIS-29 survey, especially as additional data become available for the more recent
FDA-approved innovated IGRT medical products.
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Appendix B: USIDNET Query
I have read the above data use policy and I agree to adhere by its standards.
Agree
Name
Niedre Heckman
Position
Doctoral Student - Public Health
Institution
Walden University
Email
niedre.heckman@waldenu.edu
I agree to allow the Registry Manager to contact me for follow-up data in the future.



Agree

Purpose of Query




Research for publication
Improved understanding of diseases (personal knowledge gain)

What is your overall question (briefly)?
What is the change in target audience (patients and caregivers) psychosocial perspectives as a result of
treatment of PIDD with commercially available biologic therapies delivered through the subcutaneous
route?
What study population do you want to capture?
All PIDD patients; caregivers
How might the information obtained from the USIDNET registry benefit the primary
immunodeficiency community?
The information could help the primary immunodeficiency community understand changes (hopefully
improvements) in quality of life (QOL) parameters resulting from using different therapies. For example,
patient perspectives can inform drug development and even the regulatory process for drug approval.
Once the drug is developed and on the market, which of the patient perspectives (specifically related to
social parameters measured with instruments measuring QOL parameters) shifted as a result of using a
given drug? Such knowledge could be useful for refining drug development protocol and regulatory
policy in the future.
Please list other individuals who will be accessing the requested USIDNET data.
I am a doctoral student and I will need to conduct this study independently. I am, however, seeking to
collaborate with IDF and was referred to USIDNET through IDF.
Patient Diagnosis Information
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Diagnosis
Age of Symptom Onset
Age of Diagnosis

Demographics






Age
Race
Ethnicity
Gender





Height
Weight
BMI

Vitals

Patient Infections
Yes
Please Select Fields to Include



ALL Infection Names

Non-Infectious Conditions
Yes
I would like to include fields for the following conditions:







Constitutional
Gastrointestinal
Neurologic
Psychosocial
Skin

If you are interested in specific noninfectious conditions, please list in the space below.
records that contain PROMIS-29 QOL data (scores); educational attainment; household income; zip
code; and
SF-36; SGRQ; GHQ-12; EQ-5D; or other QOL measures such as those in the CVID_QOL Questionnaire
(Quinti, I., Pulvirenti, F., Giannantoni, P., Hajjar, J., Canter, D. L., Milito, C. et al. (2016). Development
and initial validation of a questionnaire to measure health-related quality of life in adults with Common
Variable Immune Deficiency: The CVID_QoL Questionnaire. J. Allergy Clin Immunol. Pract)
Allergic Reactions
No
Live Agent Vaccines
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No
Ig Therapy
Yes
I would like to include the following fields







Starting Age
Route
Frequency
Adverse Reactions
Dose

Dose Units




g (total)
mg / kg

If you would like to include additional fields related to Ig therapy, please note accordingly in the
space below.
Name(s) of biologic and drug products used
Anti-Infectives
No
Immunomodulator Therapy
No
Blood Transfusions
No
Surgical Procedures
No
Non-Surgical Treatments
No
Complete Blood Count
No
Lymphocyte Phenotype
No
Memory B Cell Phenotype
No
Immunoglobulin Evaluations
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No
Antibody Response
No
Pneumococcal Vaccine
No
TRECs
No
Lymphocyte Function
No
Delayed Hypersensitivity Skin Testing
No
Complement Function (CH50)
No
Phagocyte Function
No
Stem Cell Transplants
No
Solid Organ Transplants
No
Gene Therapy
No
Family History
Yes
I would like to include the following fields




Relation
Diagnosis

Genetic Information
Yes
I would like to include the following fields



Pattern of Inheritance
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Gene Mutation

Quality of Life Data
Yes
I would like to include the following fields






Alive / Dead
Disabilities
Days in hospital related to PIDD
Lansky/Karnofsky Index

